{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:40:51Z","timestamp":1792194051410,"version":"4.4.0"},"reference-count":272,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-026-01011-0","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:47:31Z","timestamp":1792190851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting myeloid cell plasticity and metabolic reprogramming to alleviate T cell dysfunction and exhaustion-associated states and enhance immune checkpoint blockade therapy"],"prefix":"10.1186","volume":"14","author":[{"given":"Mingxing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixian","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5320-0725","authenticated-orcid":false,"given":"Yi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"6382","key":"1011_CR1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Sci (New York, N.Y.). 2018;359(6382):1350\u201355. https:\/\/doi.org\/10.1126\/science.aar4060.","journal-title":"Sci (New York, N.Y.)"},{"issue":"6230","key":"1011_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Sci (New York, N.Y.). 2015;348(6230):56\u201361. https:\/\/doi.org\/10.1126\/science.aaa8172.","journal-title":"Sci (New York, N.Y.)"},{"issue":"4","key":"1011_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323. https:\/\/doi.org\/10.1016\/j.cell.2017.01.017.","journal-title":"Cell"},{"issue":"4","key":"1011_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 2020;37(4):443\u201355. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.017.","journal-title":"Cancer Cell"},{"issue":"8","key":"1011_CR5","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486\u201399. https:\/\/doi.org\/10.1038\/nri3862.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"1011_CR6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, et al. Defining \u2018T cell exhaustion\u2019. Nat Rev Immunol. 2019;19(11):665\u201374. https:\/\/doi.org\/10.1038\/s41577-019-0221-9.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"1011_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","volume":"31","author":"KG Anderson","year":"2017","unstructured":"Anderson KG, Stromnes IM, Greenberg PD. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell. 2017;31(3):311\u201325. https:\/\/doi.org\/10.1016\/j.ccell.2017.02.008.","journal-title":"Cancer Cell"},{"issue":"5","key":"1011_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541\u201350. https:\/\/doi.org\/10.1038\/s41591-018-0014-x.","journal-title":"Nat Med"},{"issue":"6","key":"1011_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19(6):369\u201382. https:\/\/doi.org\/10.1038\/s41577-019-0127-6.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1011_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","volume":"30","author":"I Vitale","year":"2019","unstructured":"Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30(1):36\u201350. https:\/\/doi.org\/10.1016\/j.cmet.2019.06.001.","journal-title":"Cell MetabCell Metab"},{"issue":"6230","key":"1011_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Sci (New York, N.Y.). 2015;348(6230):74\u201380. https:\/\/doi.org\/10.1126\/science.aaa6204.","journal-title":"Sci (New York, N.Y.)"},{"issue":"7637","key":"1011_CR12","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer\u2013immune set point. Nature. 2017;541(7637):321\u201330. https:\/\/doi.org\/10.1038\/nature21349.","journal-title":"Nature"},{"issue":"6","key":"1011_CR13","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang CH, Qiu J, O\u2019sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(6):1229\u201341. https:\/\/doi.org\/10.1016\/j.cell.2015.08.016.","journal-title":"Cell"},{"issue":"2","key":"1011_CR14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","volume":"45","author":"NE Scharping","year":"2016","unstructured":"Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive Intratumoral T cell metabolic insufficiency and dysfunction. Immunity. 2016;45(2):374\u201388. https:\/\/doi.org\/10.1016\/j.immuni.2016.07.009.","journal-title":"Immunity"},{"issue":"7858","key":"1011_CR15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41586-021-03442-1","volume":"593","author":"BI Reinfeld","year":"2021","unstructured":"Reinfeld BI, Madden MZ, Wolf MM, Chytil A, Bader JE, Patterson AR, et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature. 2021;593(7858):282\u201388. https:\/\/doi.org\/10.1038\/s41586-021-03442-1.","journal-title":"Nature"},{"issue":"10","key":"1011_CR16","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.1937","volume":"11","author":"SK Biswas","year":"2010","unstructured":"Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889\u201396. https:\/\/doi.org\/10.1038\/ni.1937.","journal-title":"Nat Immunol"},{"issue":"12","key":"1011_CR17","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41577-021-00541-y","volume":"21","author":"K DePeaux","year":"2021","unstructured":"DePeaux K, Delgoffe GM. Metabolic barriers to cancer immunotherapy. Nat Rev Immunol. 2021;21(12):785\u201397. https:\/\/doi.org\/10.1038\/s41577-021-00541-y.","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"1011_CR18","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","volume":"17","author":"L Cassetta","year":"2018","unstructured":"Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17(12):887\u2013904. https:\/\/doi.org\/10.1038\/nrd.2018.169.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"1011_CR19","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41577-019-0140-9","volume":"19","author":"D O\u2019sullivan","year":"2019","unstructured":"O\u2019sullivan D, Sanin DE, Pearce EJ, Pearce EL. Metabolic interventions in the immune response to cancer. Nat Rev Immunol. 2019;19(5):324\u201335. https:\/\/doi.org\/10.1038\/s41577-019-0140-9.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1011_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.immuni.2014.06.013","volume":"41","author":"S Epelman","year":"2014","unstructured":"Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. Immunity. 2014;41(1):21\u201335. https:\/\/doi.org\/10.1016\/j.immuni.2014.06.013.","journal-title":"Immunity"},{"issue":"7868","key":"1011_CR21","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41586-021-03651-8","volume":"595","author":"M Casanova-Acebes","year":"2021","unstructured":"Casanova-Acebes M, Dalla E, Leader AM, LeBerichel J, Nikolic J, Morales BM, et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. Nature. 2021;595(7868):578\u201384. https:\/\/doi.org\/10.1038\/s41586-021-03651-8.","journal-title":"Nature"},{"issue":"6186","key":"1011_CR22","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.1252510","volume":"344","author":"RA Franklin","year":"2014","unstructured":"Franklin RA, Liao W, Sarkar A, Kim MV, Bivona MR, Liu K, et al. The cellular and molecular origin of tumor-associated macrophages. Sci (New York, N.Y.). 2014;344(6186):921\u201325. https:\/\/doi.org\/10.1126\/science.1252510.","journal-title":"Sci (New York, N.Y.)"},{"issue":"5","key":"1011_CR23","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.immuni.2019.03.009","volume":"50","author":"R Zilionis","year":"2019","unstructured":"Zilionis R, Engblom C, Pfirschke C, Savova V, Zemmour D, Saatcioglu HD, et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity. 2019;50(5):1317\u201334.e10. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.009.","journal-title":"Immunity"},{"issue":"4","key":"1011_CR24","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.cell.2020.06.032","volume":"182","author":"Y Katzenelenbogen","year":"2020","unstructured":"Katzenelenbogen Y, Sheban F, Yalin A, Yofe I, Svetlichnyy D, Jaitin DA, et al. Coupled scRNA-Seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer. Cell. 2020;182(4):872\u201385.e19. https:\/\/doi.org\/10.1016\/j.cell.2020.06.032.","journal-title":"Cell"},{"issue":"7","key":"1011_CR25","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.cell.2022.02.021","volume":"185","author":"RN Ramos","year":"2022","unstructured":"Ramos RN, Missolo-Koussou Y, Gerber-Ferder Y, Bromley CP, Bugatti M, N\u00fa\u00f1ez NG, et al. Tissue-resident FOLR2(+) macrophages associate with CD8(+) T cell infiltration in human breast cancer. Cell. 2022;185(7):1189\u2013207.e1125. https:\/\/doi.org\/10.1016\/j.cell.2022.02.021.","journal-title":"Cell"},{"issue":"3","key":"1011_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccr.2005.08.002","volume":"8","author":"MD De Palma","year":"2005","unstructured":"De Palma MD, Venneri MA, Galli R, Sergi LS, Politi LS, Sampaolesi M, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 2005;8(3):211\u201326. https:\/\/doi.org\/10.1016\/j.ccr.2005.08.002.","journal-title":"Cancer Cell"},{"issue":"7","key":"1011_CR27","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.4049\/jimmunol.1002802","volume":"186","author":"SB Coffelt","year":"2011","unstructured":"Coffelt SB, Chen YY, Muthana M, Welford AF, Tal AO, Scholz A, et al. Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion. J Immunol (Baltimore, Md, 1950) 2011;186(7):4183\u201390. https:\/\/doi.org\/10.4049\/jimmunol.1002802.","journal-title":"J Immunol"},{"issue":"5","key":"1011_CR28","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.celrep.2018.04.007","volume":"23","author":"EN Arwert","year":"2018","unstructured":"Arwert EN, Harney AS, Entenberg D, Wang Y, Sahai E, Pollard JW, et al. A unidirectional transition from migratory to perivascular macrophage is required for tumor cell intravasation. Cell Rep. 2018;23(5):1239\u201348. https:\/\/doi.org\/10.1016\/j.celrep.2018.04.007.","journal-title":"Cell Rep"},{"key":"1011_CR29","doi-asserted-by":"publisher","unstructured":"Opzoomer JW, Anstee JE, Dean I, Hill EJ, Bouybayoune I, Caron J, et al. Macrophages orchestrate the expansion of a proangiogenic perivascular niche during cancer progression. Sci Adv. 2021;7(45):eabg9518. https:\/\/doi.org\/10.1126\/sciadv.abg9518.","DOI":"10.1126\/sciadv.abg9518"},{"issue":"8","key":"1011_CR30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485\u201398. https:\/\/doi.org\/10.1038\/s41577-020-00490-y.","journal-title":"Nat Rev Immunol"},{"key":"1011_CR31","doi-asserted-by":"publisher","unstructured":"Casbon AJ, Reynaud D, Park C, Khuc E, Gan DD, Schepers K, et al. Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc Natl Acad Sci USA. 2015;112(6):E566\u2013575. https:\/\/doi.org\/10.1073\/pnas.1424927112.","DOI":"10.1073\/pnas.1424927112"},{"key":"1011_CR32","doi-asserted-by":"publisher","unstructured":"Waight JD, Hu Q, Miller A, Liu S, Abrams SI. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One. 2011;6(11):e27690. https:\/\/doi.org\/10.1371\/journal.pone.0027690.","DOI":"10.1371\/journal.pone.0027690"},{"issue":"2","key":"1011_CR33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ccell.2015.07.006","volume":"28","author":"L Strauss","year":"2015","unstructured":"Strauss L, Sangaletti S, Consonni FM, Szebeni G, Morlacchi S, Totaro MG, et al. \u201cRORC1 Regulates Tumor-promoting \u201cEmergency\u201d Granulo-monocytopoiesis. Cancer Cell. 2015;28(2):253\u201369. https:\/\/doi.org\/10.1016\/j.ccell.2015.07.006.","journal-title":"Cancer Cell"},{"issue":"6","key":"1011_CR34","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","volume":"29","author":"CW Steele","year":"2016","unstructured":"Steele CW, Karim SA, Leach JDG, Bailey P, Upstill-Goddard R, Rishi L, et al. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell. 2016;29(6):832\u201345. https:\/\/doi.org\/10.1016\/j.ccell.2016.04.014.","journal-title":"Cancer Cell"},{"issue":"2","key":"1011_CR35","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/nri.2017.105","volume":"18","author":"V Papayannopoulos","year":"2018","unstructured":"Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol. 2018;18(2):134\u201347. https:\/\/doi.org\/10.1038\/nri.2017.105.","journal-title":"Nat Rev Immunol"},{"issue":"7814","key":"1011_CR36","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41586-020-2394-6","volume":"583","author":"L Yang","year":"2020","unstructured":"Yang L, Liu Q, Zhang X, Liu X, Zhou B, Chen J, et al. DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25. Nature. 2020;583(7814):133\u201338. https:\/\/doi.org\/10.1038\/s41586-020-2394-6.","journal-title":"Nature"},{"key":"1011_CR37","doi-asserted-by":"publisher","unstructured":"Albrengues J, Shields MA, Ng D, Park CG, Ambrico A, Poindexter ME, et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Sci (New York, N.Y.). 2018;361(6409). https:\/\/doi.org\/10.1126\/science.aao4227.","DOI":"10.1126\/science.aao4227"},{"issue":"5","key":"1011_CR38","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.immuni.2020.03.001","volume":"52","author":"\u00c1 Teijeira","year":"2020","unstructured":"Teijeira \u00c1, Garasa S, Gato M, Alfaro C, Migueliz I, Cirella A, et al. CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity. Immunity. 2020;52(5):856\u201371.e8. https:\/\/doi.org\/10.1016\/j.immuni.2020.03.001.","journal-title":"Immunity"},{"key":"1011_CR39","doi-asserted-by":"publisher","first-page":"785222","DOI":"10.3389\/fimmu.2021.785222","volume":"12","author":"C Kaltenmeier","year":"2021","unstructured":"Kaltenmeier C, Yazdani HO, Morder K, Geller DA, Simmons RL, Tohme S. Neutrophil extracellular traps promote T cell exhaustion in the tumor microenvironment. Front Immunol. 2021;12:785222. https:\/\/doi.org\/10.3389\/fimmu.2021.785222.","journal-title":"Front Immunol"},{"key":"1011_CR40","doi-asserted-by":"publisher","unstructured":"Rayes RF, Mouhanna JG, Nicolau I, Bourdeau F, Giannias B, Rousseau S, et al. Primary tumors induce neutrophil extracellular traps with targetable metastasis-promoting effects. JCI Insight. 2019;4(16). https:\/\/doi.org\/10.1172\/jci.insight.128008.","DOI":"10.1172\/jci.insight.128008"},{"issue":"1","key":"1011_CR41","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","volume":"7","author":"V Bronte","year":"2016","unstructured":"Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7(1):12150. https:\/\/doi.org\/10.1038\/ncomms12150.","journal-title":"Nat Commun"},{"issue":"2","key":"1011_CR42","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","volume":"19","author":"F Veglia","year":"2018","unstructured":"Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19(2):108\u201319. https:\/\/doi.org\/10.1038\/s41590-017-0022-x.","journal-title":"Nat Immunol"},{"issue":"3","key":"1011_CR43","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208\u201320. https:\/\/doi.org\/10.1016\/j.it.2016.01.004.","journal-title":"Trends Immunol"},{"issue":"4","key":"1011_CR44","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1158\/0008-5472.Can-11-1792","volume":"72","author":"AM Lesokhin","year":"2012","unstructured":"Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res. 2012;72(4):876\u201386. https:\/\/doi.org\/10.1158\/0008-5472.Can-11-1792.","journal-title":"Cancer Res"},{"issue":"9","key":"1011_CR45","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1172\/jci80006","volume":"125","author":"S Ugel","year":"2015","unstructured":"Ugel S, De Sanctis FD, Mandruzzato S, Bronte V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin InvestJournal Clin Investigation. 2015;125(9):3365\u201376. https:\/\/doi.org\/10.1172\/jci80006.","journal-title":"J Clin InvestJournal Clin Investigation"},{"issue":"1","key":"1011_CR46","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41591-025-04060-4","volume":"32","author":"Z Li","year":"2026","unstructured":"Li Z, Li Y, Xiang J, Wang X, Yang S, Zhang X, et al. AI-enabled virtual spatial proteomics from histopathology for interpretable biomarker discovery in lung cancer. Nat Med. 2026;32(1):231\u201344. https:\/\/doi.org\/10.1038\/s41591-025-04060-4.","journal-title":"Nat Med"},{"key":"1011_CR47","doi-asserted-by":"publisher","unstructured":"Chen P, Geng H, Ma B, Zhang Y, Zhu Z, Li M, et al. Integrating spatial omics and single-cell mass spectrometry imaging reveals tumor\u2013host metabolic interplay in hepatocellular carcinoma. Proc Natl Acad Sci USA. 2025;122(31):e2505789122. https:\/\/doi.org\/10.1073\/pnas.2505789122.","DOI":"10.1073\/pnas.2505789122"},{"issue":"12","key":"1011_CR48","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1158\/2159-8290.Cd-23-0299","volume":"13","author":"I Yofe","year":"2023","unstructured":"Yofe I, Shami T, Cohen N, Landsberger T, Sheban F, Stoler-Barak L, et al. Spatial and temporal mapping of breast cancer lung metastases identify TREM2 macrophages as regulators of the metastatic boundary. Cancer DiscovCancer Discov. 2023;13(12):2610\u201331. https:\/\/doi.org\/10.1158\/2159-8290.Cd-23-0299.","journal-title":"Cancer DiscovCancer Discov"},{"issue":"18","key":"1011_CR49","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","volume":"184","author":"K Pelka","year":"2021","unstructured":"Pelka K, Hofree M, Chen JH, Sarkizova S, Pirl JD, Jorgji V, et al. Spatially organized multicellular immune hubs in human colorectal cancer. Cell. 2021;184(18):4734\u201352.e20. https:\/\/doi.org\/10.1016\/j.cell.2021.08.003.","journal-title":"Cell"},{"issue":"7","key":"1011_CR50","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1158\/0008-5472.Can-19-2994","volume":"80","author":"P Su","year":"2020","unstructured":"Su P, Wang Q, Bi E, Ma X, Liu L, Yang M, et al. Enhanced lipid accumulation and metabolism are required for the differentiation and activation of tumor-associated macrophages. Cancer Res. 2020;80(7):1438\u201350. https:\/\/doi.org\/10.1158\/0008-5472.Can-19-2994.","journal-title":"Cancer Res"},{"issue":"3","key":"1011_CR51","doi-asserted-by":"publisher","first-page":"189588","DOI":"10.1016\/j.bbcan.2026.189588","volume":"1881","author":"D Li","year":"2026","unstructured":"Li D, Wu L, Li Y. Targeting cholesterol metabolism: a core regulator of tumor-associated macrophage plasticity and immunotherapy response. Biochim et Biophys Acta (BBA) - Rev Cancer. 2026;1881(3):189588. https:\/\/doi.org\/10.1016\/j.bbcan.2026.189588.","journal-title":"Biochim et Biophys Acta (BBA) - Rev Cancer"},{"issue":"7596","key":"1011_CR52","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nature17412","volume":"531","author":"W Yang","year":"2016","unstructured":"Yang W, Bai Y, Xiong Y, Zhang J, Chen S, Zheng X, et al. Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature. 2016;531(7596):651\u201355. https:\/\/doi.org\/10.1038\/nature17412.","journal-title":"Nature"},{"key":"1011_CR53","doi-asserted-by":"publisher","unstructured":"Wu H, Han Y, Rodriguez Sillke YR, Deng H, Siddiqui S, Treese C, et al. Lipid droplet-dependent fatty acid metabolism controls the immune suppressive phenotype of tumor-associated macrophages. EMBO Mol Med. 2019;11(11):e10698. https:\/\/doi.org\/10.15252\/emmm.201910698.","DOI":"10.15252\/emmm.201910698"},{"issue":"6","key":"1011_CR54","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.cmet.2019.02.016","volume":"29","author":"P Goossens","year":"2019","unstructured":"Goossens P, Rodriguez-Vita J, Etzerodt A, Masse M, Rastoin O, Gouirand V, et al. Membrane cholesterol efflux drives tumor-associated macrophage reprogramming and tumor progression. Cell Metab. 2019;29(6):1376\u201389.e4. https:\/\/doi.org\/10.1016\/j.cmet.2019.02.016.","journal-title":"Cell MetabCell Metab"},{"issue":"1","key":"1011_CR55","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","volume":"30","author":"X Ma","year":"2019","unstructured":"Ma X, Bi E, Lu Y, Su P, Huang C, Liu L, et al. Cholesterol induces CD8(+) T cell exhaustion in the tumor microenvironment. Cell Metab. 2019;30(1):143\u201356.e145. https:\/\/doi.org\/10.1016\/j.cmet.2019.04.002.","journal-title":"Cell Metab"},{"issue":"7754","key":"1011_CR56","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41586-019-1118-2","volume":"569","author":"F Veglia","year":"2019","unstructured":"Veglia F, Tyurin VA, Blasi M, De Leo AD, Kossenkov AV, Donthireddy L, et al. Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature. 2019;569(7754):73\u201378. https:\/\/doi.org\/10.1038\/s41586-019-1118-2.","journal-title":"Nature"},{"key":"1011_CR57","doi-asserted-by":"publisher","unstructured":"Al-Khami AA, Zheng L, Del Valle LD, Hossain F, Wyczechowska D, Zabaleta J, et al. Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells. Oncoimmunology. 2017;6(10):e1344804. https:\/\/doi.org\/10.1080\/2162402x.2017.1344804.","DOI":"10.1080\/2162402x.2017.1344804"},{"issue":"11","key":"1011_CR58","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/2326-6066.Cir-15-0036","volume":"3","author":"F Hossain","year":"2015","unstructured":"Hossain F, Al-Khami AA, Wyczechowska D, Hernandez C, Zheng L, Reiss K, et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol Res. 2015;3(11):1236\u201347. https:\/\/doi.org\/10.1158\/2326-6066.Cir-15-0036.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"1011_CR59","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.apsb.2022.10.027","volume":"13","author":"M Zheng","year":"2023","unstructured":"Zheng M, Zhang W, Chen X, Guo H, Wu H, Xu Y, et al. The impact of lipids on the cancer\u2013immunity cycle and strategies for modulating lipid metabolism to improve cancer immunotherapy. Acta pharmaceutica Sin B. 2023;13(4):1488\u201397. https:\/\/doi.org\/10.1016\/j.apsb.2022.10.027.","journal-title":"Acta pharmaceutica Sin B"},{"key":"1011_CR60","doi-asserted-by":"publisher","first-page":"1749965","DOI":"10.3389\/fimmu.2026.1749965","volume":"17","author":"S Dash","year":"2026","unstructured":"Dash S, Firmanty P, Chomczyk M, Mohanty V, Ma W, Baran N. Targeting MDSCs in cancer: emerging immunotherapeutic and metabolic strategies. Front Immunol. 2026;17:1749965. https:\/\/doi.org\/10.3389\/fimmu.2026.1749965.","journal-title":"Front Immunol"},{"key":"1011_CR61","doi-asserted-by":"publisher","unstructured":"Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S, Alicea-Torres K, et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol. 2016;1(2). https:\/\/doi.org\/10.1126\/sciimmunol.aaf8943.","DOI":"10.1126\/sciimmunol.aaf8943"},{"key":"1011_CR62","doi-asserted-by":"publisher","first-page":"1728354","DOI":"10.3389\/fimmu.2025.1728354","volume":"16","author":"W Liu","year":"2025","unstructured":"Liu W, Wang Z, Li Z, Li S, Shi X, Xu Y, et al. Lipid metabolic reprogramming in the tumor microenvironment and its mechanistic role in immunosuppressive cells. Front Immunol. 2025;16:1728354. https:\/\/doi.org\/10.3389\/fimmu.2025.1728354.","journal-title":"Front Immunol"},{"issue":"8","key":"1011_CR63","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1161\/atvbaha.114.303887","volume":"34","author":"S Bekkering","year":"2014","unstructured":"Bekkering S, Quintin J, Joosten LAB, van der Meer JWM, Netea MG, Riksen NP. Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes. ATVB. 2014;34(8):1731\u201338. https:\/\/doi.org\/10.1161\/atvbaha.114.303887.","journal-title":"ATVB"},{"issue":"1","key":"1011_CR64","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4049\/immunohorizons.2300101","volume":"8","author":"KKY Ting","year":"2024","unstructured":"Ting KKY, Yu P, Iyayi M, Dow R, Hyduk SJ, Floro E, et al. Oxidized low-density lipoprotein accumulation in Macrophages impairs lipopolysaccharide-induced activation of AKT2, ATP citrate lyase, acetyl\u2013coenzyme a production, and inflammatory gene H3K27 acetylation. ImmunoHorizons. 2024;8(1):57\u201373. https:\/\/doi.org\/10.4049\/immunohorizons.2300101.","journal-title":"ImmunoHorizons"},{"key":"1011_CR65","doi-asserted-by":"publisher","first-page":"868788","DOI":"10.3389\/fcvm.2022.868788","volume":"9","author":"H Yang","year":"2022","unstructured":"Yang H, Sun Y, Li Q, Jin F, Dai Y. Diverse epigenetic regulations of Macrophages in atherosclerosis. Front Cardiovasc Med. 2022;9:868788. https:\/\/doi.org\/10.3389\/fcvm.2022.868788.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"1011_CR66","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.immuni.2017.07.020","volume":"47","author":"W Pan","year":"2017","unstructured":"Pan W, Zhu S, Qu K, Meeth K, Cheng J, He K, et al. The DNA methylcytosine dioxygenase Tet2 sustains immunosuppressive function of tumor-infiltrating myeloid cells to promote melanoma progression. Immunity. 2017;47(2):284\u201397.e5. https:\/\/doi.org\/10.1016\/j.immuni.2017.07.020.","journal-title":"Immunity"},{"issue":"15","key":"1011_CR67","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1158\/0008-5472.Can-19-3670","volume":"80","author":"AD Smith","year":"2020","unstructured":"Smith AD, Lu C, Payne D, Paschall AV, Klement JD, Redd PS, et al. Autocrine IL6-mediated activation of the STAT3\u2013DNMT Axis silences the TNF\u03b1\u2013RIP1 necroptosis pathway to sustain survival and accumulation of myeloid-derived suppressor cells. Cancer Res. 2020;80(15):3145\u201356. https:\/\/doi.org\/10.1158\/0008-5472.Can-19-3670.","journal-title":"Cancer Res"},{"issue":"19","key":"1011_CR68","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1002\/1873-3468.12786","volume":"591","author":"GFP Bories","year":"2017","unstructured":"Bories GFP, Leitinger N. Macrophage metabolism in atherosclerosis. FEBS Lett. 2017;591(19):3042\u201360. https:\/\/doi.org\/10.1002\/1873-3468.12786.","journal-title":"FEBS Lett"},{"issue":"6","key":"1011_CR69","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3390\/antiox14060726","volume":"14","author":"X Zhang","year":"2025","unstructured":"Zhang X, Ye X, Jin H. Oxidized low-density lipoprotein as a potential target for enhancing immune checkpoint inhibitor therapy in microsatellite-stable colorectal cancer. Antioxid (Basel, Switz). 2025;14(6):726. https:\/\/doi.org\/10.3390\/antiox14060726.","journal-title":"Antioxid (Basel, Switz)"},{"issue":"2","key":"1011_CR70","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1158\/2326-6066.Cir-20-0358","volume":"9","author":"N Khojandi","year":"2021","unstructured":"Khojandi N, Kuehm LM, Piening A, Donlin MJ, Hsueh EC, Schwartz TL, et al. Oxidized lipoproteins promote resistance to cancer immunotherapy Independent of patient obesity. Cancer Immunol Res. 2021;9(2):214\u201326. https:\/\/doi.org\/10.1158\/2326-6066.Cir-20-0358.","journal-title":"Cancer Immunol Res"},{"issue":"19","key":"1011_CR71","doi-asserted-by":"publisher","first-page":"5336","DOI":"10.1016\/j.cell.2024.07.030","volume":"187","author":"DJ Kloosterman","year":"2024","unstructured":"Kloosterman DJ, Erbani J, Boon M, Farber M, Handgraaf SM, Ando-Kuri M, et al. Macrophage-mediated myelin recycling fuels brain cancer malignancy. Cell. 2024;187(19):5336\u201356.e30. https:\/\/doi.org\/10.1016\/j.cell.2024.07.030.","journal-title":"Cell"},{"key":"1011_CR72","doi-asserted-by":"publisher","unstructured":"Bi C, Lan S, Sun Z, Fan F, Luo X. cRGD-functionalized macrophage extracellular vesicles loaded with GSK2033 enhance T cell antitumor immunity in GBM by disrupting the LXR\/ABCA1-mediated myelin lipid transfer axis. J Nanobiotechnol. 2026;24(1). https:\/\/doi.org\/10.1186\/s12951-026-04116-8.","DOI":"10.1186\/s12951-026-04116-8"},{"issue":"12","key":"1011_CR73","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/s41593-020-00717-0","volume":"23","author":"A Marco","year":"2020","unstructured":"Marco A, Meharena HS, Dileep V, Raju RM, Davila-Velderrain J, Zhang AL, et al. Mapping the epigenomic and transcriptomic interplay during memory formation and recall in the hippocampal engram ensemble. Nat Neurosci. 2020;23(12):1606\u201317. https:\/\/doi.org\/10.1038\/s41593-020-00717-0.","journal-title":"Nat Neurosci"},{"issue":"12","key":"1011_CR74","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41423-025-01365-9","volume":"22","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Yu S, Yeernuer D, Liu W, Xu Z, Feng W, et al. IL33-induced lipid droplet formation in mature low-density neutrophils drives colorectal cancer liver metastasis. Cell Mol Immunol. 2025;22(12):1598\u2013614. https:\/\/doi.org\/10.1038\/s41423-025-01365-9.","journal-title":"Cell Mol Immunol"},{"issue":"7","key":"1011_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20892\/j.issn.2095-3941.2025.0115","volume":"22","author":"Z Lin","year":"2025","unstructured":"Lin Z, Chang C, Zhao S, Fang L, Wang P. Amino acids shape the metabolic and immunologic landscape in the tumor immune microenvironment: from molecular mechanisms to therapeutic strategies. Cancer Biol Med. 2025;22(7):1\u201321. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2025.0115.","journal-title":"Cancer Biol Med"},{"key":"1011_CR76","doi-asserted-by":"publisher","unstructured":"Zhu L, Wu M, Feng B, Zhang Y, Xu Y, Yu L. RNA helicase SKIV2L impedes tumor immunity by reprogramming arginine metabolism of hepatocellular carcinomas. J Immunother Cancer. 2026;14(4):e014192. https:\/\/doi.org\/10.1136\/jitc-2025-014192.","DOI":"10.1136\/jitc-2025-014192"},{"issue":"10","key":"1011_CR77","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.3390\/biomedicines11102703","volume":"11","author":"ET Alexander","year":"2023","unstructured":"Alexander ET, Fahey E, Phanstiel O, Gilmour SK. Loss of anti-tumor efficacy by polyamine blocking therapy in GCN2 null mice. Biomedicines. 2023;11(10):2703. https:\/\/doi.org\/10.3390\/biomedicines11102703.","journal-title":"Biomedicines"},{"issue":"4","key":"1011_CR78","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1021\/acsnano.5c06907","volume":"20","author":"J Lee","year":"2026","unstructured":"Lee J, Kang Y, Kang S, Sun H, Yoon H, Doh J, et al. Engineering T cells with membrane-anchored nitric oxide scavengers for anticancer therapy. ACS Nano. 2026;20(4):3379\u201392. https:\/\/doi.org\/10.1021\/acsnano.5c06907.","journal-title":"ACS Nano"},{"issue":"7","key":"1011_CR79","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nm1609","volume":"13","author":"S Nagaraj","year":"2007","unstructured":"Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13(7):828\u201335. https:\/\/doi.org\/10.1038\/nm1609.","journal-title":"Nat Med"},{"issue":"10","key":"1011_CR80","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1172\/jci45862","volume":"121","author":"T Lu","year":"2011","unstructured":"Lu T, Ramakrishnan R, Altiok S, Youn JI, Cheng P, Celis E, et al. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest. 2011;121(10):4015\u201329. https:\/\/doi.org\/10.1172\/jci45862.","journal-title":"J Clin Invest"},{"issue":"10","key":"1011_CR81","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.ccell.2022.09.001","volume":"40","author":"EN Tcyganov","year":"2022","unstructured":"Tcyganov EN, Sanseviero E, Marvel D, Beer T, Tang HY, Hembach P, et al. Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy. Cancer Cell. 2022;40(10):1173\u201389.e6. https:\/\/doi.org\/10.1016\/j.ccell.2022.09.001.","journal-title":"Cancer Cell"},{"issue":"13","key":"1011_CR82","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.3390\/molecules30132802","volume":"30","author":"A My\u015bliwiec","year":"2025","unstructured":"My\u015bliwiec A, Bartusik-Aebisher D, Aebisher D. The role of nitric oxide in cancer treatment: ally or foe? Mol (Basel, Switz). 2025;30(13):2802. https:\/\/doi.org\/10.3390\/molecules30132802.","journal-title":"Mol (Basel, Switz)"},{"issue":"6","key":"1011_CR83","doi-asserted-by":"publisher","first-page":"104827","DOI":"10.1016\/j.jbc.2023.104827","volume":"299","author":"L Zeitler","year":"2023","unstructured":"Zeitler L, Murray PJ. IL4i1 and IDO1: oxidases that control a tryptophan metabolic nexus in cancer. J Biol Chem. 2023;299(6):104827. https:\/\/doi.org\/10.1016\/j.jbc.2023.104827.","journal-title":"J Biol Chem"},{"issue":"3","key":"1011_CR84","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2767-9764.Crc-23-0513","volume":"4","author":"LS Crump","year":"2024","unstructured":"Crump LS, Floyd JL, Kuo LW, Post MD, Bickerdike M, O\u2019neill K, et al. Targeting tryptophan catabolism in ovarian cancer to attenuate macrophage infiltration and PD-L1 expression. Cancer Res Commun. 2024;4(3):822\u201333. https:\/\/doi.org\/10.1158\/2767-9764.Crc-23-0513.","journal-title":"Cancer Res Commun"},{"issue":"5","key":"1011_CR85","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.cell.2020.07.038","volume":"182","author":"A Sadik","year":"2020","unstructured":"Sadik A, Somarribas Patterson LFS, \u00d6zt\u00fcrk S, Mohapatra SR, Panitz V, Secker PF, et al. IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression. Cell. 2020;182(5):1252\u201370.e34. https:\/\/doi.org\/10.1016\/j.cell.2020.07.038.","journal-title":"Cell"},{"issue":"1","key":"1011_CR86","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1038\/s41467-020-17750-z","volume":"11","author":"LF Campesato","year":"2020","unstructured":"Campesato LF, Budhu S, Tchaicha J, Weng CH, Gigoux M, Cohen IJ, et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nat Commun. 2020;11(1):4011. https:\/\/doi.org\/10.1038\/s41467-020-17750-z.","journal-title":"Nat Commun"},{"issue":"2","key":"1011_CR87","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.immuni.2022.01.006","volume":"55","author":"K Hezaveh","year":"2022","unstructured":"Hezaveh K, Shinde RS, Kl\u00f6tgen A, Halaby MJ, Lamorte S, Ciudad MT, et al. Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity. Immunity. 2022;55(2):324\u201340.e8. https:\/\/doi.org\/10.1016\/j.immuni.2022.01.006.","journal-title":"Immunity"},{"issue":"3","key":"1011_CR88","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3390\/cancers16030472","volume":"16","author":"BD Griffith","year":"2024","unstructured":"Griffith BD, Frankel TL. The aryl hydrocarbon receptor: impact on the tumor immune microenvironment and modulation as a potential therapy. Cancers. 2024;16(3):472. https:\/\/doi.org\/10.3390\/cancers16030472.","journal-title":"Cancers"},{"issue":"6468","key":"1011_CR89","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1126\/science.aav2588","volume":"366","author":"RD Leone","year":"2019","unstructured":"Leone RD, Zhao L, Englert JM, Sun IM, Oh MH, Sun IH, et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Sci (New York, N.Y.). 2019;366(6468):1013\u201321. https:\/\/doi.org\/10.1126\/science.aav2588.","journal-title":"Sci (New York, N.Y.)"},{"issue":"7","key":"1011_CR90","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1172\/jci131859","volume":"130","author":"MH Oh","year":"2020","unstructured":"Oh MH, Sun IH, Zhao L, Leone RD, Sun IM, Xu W, et al. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J Clin InvestJournal Clin Investigation. 2020;130(7):3865\u201384. https:\/\/doi.org\/10.1172\/jci131859.","journal-title":"J Clin InvestJournal Clin Investigation"},{"issue":"5","key":"1011_CR91","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41423-024-01134-0","volume":"21","author":"Z Cai","year":"2024","unstructured":"Cai Z, Li W, Hager S, Wilson JL, Afjehi-Sadat L, Heiss EH, et al. Targeting PHGDH reverses the immunosuppressive phenotype of tumor-associated macrophages through \u03b1-ketoglutarate and mTORC1 signaling. Cell Mol Immunol. 2024;21(5):448\u201365. https:\/\/doi.org\/10.1038\/s41423-024-01134-0.","journal-title":"Cell Mol Immunol"},{"issue":"9","key":"1011_CR92","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/ni.3796","volume":"18","author":"PS Liu","year":"2017","unstructured":"Liu PS, Wang H, Li X, Chao T, Teav T, Christen S, et al. \u03b1-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat Immunol. 2017;18(9):985\u201394. https:\/\/doi.org\/10.1038\/ni.3796.","journal-title":"Nat Immunol"},{"issue":"7","key":"1011_CR93","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/j.celrep.2017.07.054","volume":"20","author":"EM Palmieri","year":"2017","unstructured":"Palmieri EM, Menga A, Mart\u00edn-P\u00e9rez R, Quinto A, Riera-Domingo C, De Tullio GD, et al. Pharmacologic or genetic targeting of glutamine synthetase skews Macrophages toward an M1-like phenotype and inhibits tumor metastasis. Cell Rep. 2017;20(7):1654\u201366. https:\/\/doi.org\/10.1016\/j.celrep.2017.07.054.","journal-title":"Cell Rep"},{"issue":"1","key":"1011_CR94","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13046-024-02994-0","volume":"43","author":"B Wang","year":"2024","unstructured":"Wang B, Pei J, Xu S, Liu J, Yu J. A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle. J Exp Clin Cancer Res. 2024;43(1):74. https:\/\/doi.org\/10.1186\/s13046-024-02994-0.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1011_CR95","doi-asserted-by":"publisher","first-page":"12632","DOI":"10.1038\/ncomms12632","volume":"7","author":"CW Li","year":"2016","unstructured":"Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7(1):12632. https:\/\/doi.org\/10.1038\/ncomms12632.","journal-title":"Nat Commun"},{"issue":"11","key":"1011_CR96","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1084\/jem.20100587","volume":"207","author":"CA Corzo","year":"2010","unstructured":"Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, et al. HIF-1\u03b1 regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207(11):2439\u201353. https:\/\/doi.org\/10.1084\/jem.20100587.","journal-title":"J Exp Med"},{"issue":"7519","key":"1011_CR97","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature13490","volume":"513","author":"OR Colegio","year":"2014","unstructured":"Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513(7519):559\u201363. https:\/\/doi.org\/10.1038\/nature13490.","journal-title":"Nature"},{"issue":"12","key":"1011_CR98","doi-asserted-by":"publisher","first-page":"6350","DOI":"10.3390\/ijms22126350","volume":"22","author":"HL Penny","year":"2021","unstructured":"Penny HL, Sieow JL, Gun SY, Lau MC, Lee B, Tan J, et al. Targeting glycolysis in macrophages confers protection against pancreatic ductal adenocarcinoma. IJMS. 2021;22(12):6350. https:\/\/doi.org\/10.3390\/ijms22126350.","journal-title":"IJMS"},{"key":"1011_CR99","doi-asserted-by":"publisher","first-page":"1416472","DOI":"10.3389\/fcell.2024.1416472","volume":"12","author":"J Zhao","year":"2024","unstructured":"Zhao J, Jin D, Huang M, Ji J, Xu X, Wang F, et al. Glycolysis in the tumor microenvironment: a driver of cancer progression and a promising therapeutic target. Front Cell Dev Biol. 2024;12:1416472. https:\/\/doi.org\/10.3389\/fcell.2024.1416472.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1011_CR100","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cmet.2018.04.022","volume":"28","author":"W Li","year":"2018","unstructured":"Li W, Tanikawa T, Kryczek I, Xia H, Li G, Wu K, et al. Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB Isoform in triple-negative breast cancer. Cell MetabCell Metab. 2018;28(1):87\u2013103.e6. https:\/\/doi.org\/10.1016\/j.cmet.2018.04.022.","journal-title":"Cell MetabCell Metab"},{"issue":"1","key":"1011_CR101","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cmet.2014.12.005","volume":"21","author":"EM Palsson-McDermott","year":"2015","unstructured":"Palsson-McDermott EM, Curtis AM, Goel G, Lauterbach MR, Sheedy FJ, Gleeson LE, et al. Pyruvate kinase M2 regulates hif-1\u03b1 activity and IL-1\u03b2 induction and is a critical determinant of the warburg effect in LPS-activated macrophages. Cell Metab. 2015;21(1):65\u201380. https:\/\/doi.org\/10.1016\/j.cmet.2014.12.005.","journal-title":"Cell MetabCell Metab"},{"issue":"5","key":"1011_CR102","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.cmet.2016.09.008","volume":"24","author":"M Wenes","year":"2016","unstructured":"Wenes M, Shang M, Di Matteo MD, Goveia J, Mart\u00edn-P\u00e9rez R, Serneels J, et al. Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis. Cell Metab. 2016;24(5):701\u201315. https:\/\/doi.org\/10.1016\/j.cmet.2016.09.008.","journal-title":"Cell MetabCell Metab"},{"key":"1011_CR103","doi-asserted-by":"publisher","unstructured":"Cao J, Zeng F, Liao S, Cao L, Zhou Y. Effects of glycolysis on the polarization and function of tumor\u2011associated macrophages (Review). Int J Oncol. 2023;62(6). https:\/\/doi.org\/10.3892\/ijo.2023.5518.","DOI":"10.3892\/ijo.2023.5518"},{"key":"1011_CR104","doi-asserted-by":"publisher","first-page":"1175532","DOI":"10.3389\/fonc.2023.1175532","volume":"13","author":"SSM Mortazavi Farsani","year":"2023","unstructured":"Mortazavi Farsani SSM, Verma V. Lactate mediated metabolic crosstalk between cancer and immune cells and its therapeutic implications. Front Oncol. 2023;13:1175532. https:\/\/doi.org\/10.3389\/fonc.2023.1175532.","journal-title":"Front Oncol"},{"issue":"1","key":"1011_CR105","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","volume":"20","author":"L Xia","year":"2021","unstructured":"Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20(1):28. https:\/\/doi.org\/10.1186\/s12943-021-01316-8.","journal-title":"Mol Cancer"},{"issue":"12","key":"1011_CR106","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/s41590-018-0226-8","volume":"19","author":"T Bohn","year":"2018","unstructured":"Bohn T, Rapp S, Luther N, Klein M, Bruehl TJ, Kojima N, et al. Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages. Nat Immunol. 2018;19(12):1319\u201329. https:\/\/doi.org\/10.1038\/s41590-018-0226-8.","journal-title":"Nat Immunol"},{"issue":"7779","key":"1011_CR107","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","volume":"574","author":"D Zhang","year":"2019","unstructured":"Zhang D, Tang Z, Huang H, Zhou G, Cui C, Weng Y, et al. Metabolic regulation of gene expression by histone lactylation. Nature. 2019;574(7779):575\u201380. https:\/\/doi.org\/10.1038\/s41586-019-1678-1.","journal-title":"Nature"},{"key":"1011_CR108","doi-asserted-by":"publisher","first-page":"1697008","DOI":"10.3389\/fimmu.2025.1697008","volume":"16","author":"Q Yang","year":"2026","unstructured":"Yang Q, Yang Z, Zhao H. Lactylation in cancer: mechanistic insights, tumor microenvironment, and therapeutic horizons. Front Immunol. 2026;16:1697008. https:\/\/doi.org\/10.3389\/fimmu.2025.1697008.","journal-title":"Front Immunol"},{"issue":"5","key":"1011_CR109","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.immuni.2024.04.006","volume":"57","author":"AD De Leo","year":"2024","unstructured":"De Leo AD, Ugolini A, Yu X, Scirocchi F, Scocozza D, Peixoto B, et al. Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma. Immunity. 2024;57(5):1105\u201323.e8. https:\/\/doi.org\/10.1016\/j.immuni.2024.04.006.","journal-title":"Immunity"},{"key":"1011_CR110","doi-asserted-by":"publisher","first-page":"1395786","DOI":"10.3389\/fimmu.2024.1395786","volume":"15","author":"B Xu","year":"2024","unstructured":"Xu B, Liu Y, Li N, Geng Q. Lactate and lactylation in macrophage metabolic reprogramming: current progress and outstanding issues. Front Immunol. 2024;15:1395786. https:\/\/doi.org\/10.3389\/fimmu.2024.1395786.","journal-title":"Front Immunol"},{"issue":"2","key":"1011_CR111","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41568-020-00312-2","volume":"21","author":"X Chen","year":"2021","unstructured":"Chen X, Cubillos-Ruiz JR. Endoplasmic reticulum stress signals in the tumour and its microenvironment. Nat Rev Cancer. 2021;21(2):71\u201388. https:\/\/doi.org\/10.1038\/s41568-020-00312-2.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"1011_CR112","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.cell.2015.05.025","volume":"161","author":"JR Cubillos-Ruiz","year":"2015","unstructured":"Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, Chopra S, Perales-Puchalt A, Song M, et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell. 2015;161(7):1527\u201338. https:\/\/doi.org\/10.1016\/j.cell.2015.05.025.","journal-title":"Cell"},{"key":"1011_CR113","doi-asserted-by":"publisher","unstructured":"Batista A, Rodvold JJ, Xian S, Searles SC, Lew A, Iwawaki T, et al. IRE1\u03b1 regulates macrophage polarization, PD-L1 expression, and tumor survival. PLoS Biol. 2020;18(6):e3000687. https:\/\/doi.org\/10.1371\/journal.pbio.3000687.","DOI":"10.1371\/journal.pbio.3000687"},{"issue":"3","key":"1011_CR114","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41590-022-01145-x","volume":"23","author":"LN Raines","year":"2022","unstructured":"Raines LN, Zhao H, Wang Y, Chen HY, Gallart-Ayala H, Hsueh PC, et al. PERK is a critical metabolic hub for immunosuppressive function in macrophages. Nat Immunol. 2022;23(3):431\u201345. https:\/\/doi.org\/10.1038\/s41590-022-01145-x.","journal-title":"Nat Immunol"},{"issue":"4","key":"1011_CR115","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.immuni.2020.03.004","volume":"52","author":"E Mohamed","year":"2020","unstructured":"Mohamed E, Sierra RA, Trillo-Tinoco J, Cao Y, Innamarato P, Payne KK, et al. The unfolded protein response mediator PERK governs myeloid cell-driven immunosuppression in tumors through inhibition of STING signaling. Immunity. 2020;52(4):668\u201382.e7. https:\/\/doi.org\/10.1016\/j.immuni.2020.03.004.","journal-title":"Immunity"},{"issue":"6","key":"1011_CR116","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1172\/jci74056","volume":"124","author":"T Condamine","year":"2014","unstructured":"Condamine T, Kumar V, Ramachandran IR, Youn JI, Celis E, Finnberg N, et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R\u2013mediated apoptosis. J Clin Invest. 2014;124(6):2626\u201339. https:\/\/doi.org\/10.1172\/jci74056.","journal-title":"J Clin Invest"},{"issue":"12","key":"1011_CR117","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.trecan.2024.09.011","volume":"10","author":"H Urra","year":"2024","unstructured":"Urra H, Aravena R, Gonz\u00e1lez-Johnson L, Hetz C. The UPRising connection between endoplasmic reticulum stress and the tumor microenvironment. Trends Cancer. 2024;10(12):1161\u201373. https:\/\/doi.org\/10.1016\/j.trecan.2024.09.011.","journal-title":"Trends Cancer"},{"issue":"5","key":"1011_CR118","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1158\/1541-7786.Mcr-22-0920","volume":"21","author":"E Petrosyan","year":"2023","unstructured":"Petrosyan E, Fares J, Fernandez LG, Yeeravalli R, Dmello C, Duffy JT, et al. Endoplasmic reticulum stress in the brain tumor immune microenvironment. Mol Cancer Res: MCR. 2023;21(5):389\u201396. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-22-0920.","journal-title":"Mol Cancer Res: MCR"},{"issue":"25","key":"1011_CR119","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1038\/s41388-019-0772-z","volume":"38","author":"D Bao","year":"2019","unstructured":"Bao D, Zhao J, Zhou X, Yang Q, Chen Y, Zhu J, et al. Mitochondrial fission-induced mtDNA stress promotes tumor-associated macrophage infiltration and HCC progression. Oncogene. 2019;38(25):5007\u201320. https:\/\/doi.org\/10.1038\/s41388-019-0772-z.","journal-title":"Oncogene"},{"issue":"5","key":"1011_CR120","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/ni.3704","volume":"18","author":"EL Mills","year":"2017","unstructured":"Mills EL, Kelly B, O\u2019neill LAJ. Mitochondria are the powerhouses of immunity. Nat Immunol. 2017;18(5):488\u201398. https:\/\/doi.org\/10.1038\/ni.3704.","journal-title":"Nat Immunol"},{"issue":"6","key":"1011_CR121","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s42255-022-00591-z","volume":"4","author":"MP Murphy","year":"2022","unstructured":"Murphy MP, Bayir H, Belousov V, Chang CJ, Davies KJA, Davies MJ, et al. Guidelines for measuring reactive oxygen species and oxidative damage in cells and in vivo. Nat Metab. 2022;4(6):651\u201362. https:\/\/doi.org\/10.1038\/s42255-022-00591-z.","journal-title":"Nat Metab"},{"key":"1011_CR122","doi-asserted-by":"publisher","unstructured":"Jian SL, Chen WW, Su YC, Su YW, Chuang TH, Hsu SC, et al. Glycolysis regulates the expansion of myeloid-derived suppressor cells in tumor-bearing hosts through prevention of ROS-mediated apoptosis. Cell Death Dis. 2017;8(5):e2779. https:\/\/doi.org\/10.1038\/cddis.2017.192.","DOI":"10.1038\/cddis.2017.192"},{"issue":"1","key":"1011_CR123","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.immuni.2014.12.030","volume":"42","author":"J Blagih","year":"2015","unstructured":"Blagih J, Coulombe F, Vincent EE, Dupuy F, Galicia-V\u00e1zquez G, Yurchenko E, et al. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity. 2015;42(1):41\u201354. https:\/\/doi.org\/10.1016\/j.immuni.2014.12.030.","journal-title":"Immunity"},{"issue":"7764","key":"1011_CR124","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","volume":"571","author":"AC Scott","year":"2019","unstructured":"Scott AC, D\u00fcndar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019;571(7764):270\u201374. https:\/\/doi.org\/10.1038\/s41586-019-1324-y.","journal-title":"Nature"},{"issue":"7764","key":"1011_CR125","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, et al. TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion. Nature. 2019;571(7764):211\u201318. https:\/\/doi.org\/10.1038\/s41586-019-1325-x.","journal-title":"Nature"},{"issue":"1","key":"1011_CR126","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/ni.3313","volume":"17","author":"E Zhao","year":"2016","unstructured":"Zhao E, Maj T, Kryczek I, Li W, Wu K, Zhao L, et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol. 2016;17(1):95\u2013103. https:\/\/doi.org\/10.1038\/ni.3313.","journal-title":"Nat Immunol"},{"issue":"5","key":"1011_CR127","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.immuni.2005.03.013","volume":"22","author":"DH Munn","year":"2005","unstructured":"Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2, 3-dioxygenase. Immunity. 2005;22(5):633\u201342. https:\/\/doi.org\/10.1016\/j.immuni.2005.03.013.","journal-title":"Immunity"},{"issue":"2","key":"1011_CR128","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.cmet.2020.06.010","volume":"32","author":"B Kelly","year":"2020","unstructured":"Kelly B, Pearce EL. Amino assets: how amino acids support immunity. Cell MetabCell Metab. 2020;32(2):154\u201375. https:\/\/doi.org\/10.1016\/j.cmet.2020.06.010.","journal-title":"Cell MetabCell Metab"},{"issue":"24","key":"1011_CR129","doi-asserted-by":"publisher","first-page":"21123","DOI":"10.1074\/jbc.M110675200","volume":"277","author":"PC Rodriguez","year":"2002","unstructured":"Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC. Regulation of T cell receptor CD3zeta Chain expression byL-arginine. J Biol Chem. 2002;277(24):21123\u201329. https:\/\/doi.org\/10.1074\/jbc.M110675200.","journal-title":"J Biol Chem"},{"issue":"4","key":"1011_CR130","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1182\/blood-2006-06-031856","volume":"109","author":"PC Rodriguez","year":"2007","unstructured":"Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood. 2007;109(4):1568\u201373. https:\/\/doi.org\/10.1182\/blood-2006-06-031856.","journal-title":"Blood"},{"issue":"3","key":"1011_CR131","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","volume":"167","author":"R Geiger","year":"2016","unstructured":"Geiger R, Rieckmann JC, Wolf T, Basso C, Feng Y, Fuhrer T, et al. L-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell. 2016;167(3):829\u201342.e13. https:\/\/doi.org\/10.1016\/j.cell.2016.09.031.","journal-title":"Cell"},{"issue":"2","key":"1011_CR132","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ni.3323","volume":"17","author":"PJ Murray","year":"2016","unstructured":"Murray PJ. Amino acid auxotrophy as a system of immunological control nodes. Nat Immunol. 2016;17(2):132\u201339. https:\/\/doi.org\/10.1038\/ni.3323.","journal-title":"Nat Immunol"},{"issue":"3","key":"1011_CR133","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162\u201374. https:\/\/doi.org\/10.1038\/nri2506.","journal-title":"Nat Rev Immunol"},{"key":"1011_CR134","doi-asserted-by":"publisher","first-page":"1381919","DOI":"10.3389\/fimmu.2024.1381919","volume":"15","author":"X Fan","year":"2024","unstructured":"Fan X, Peng H, Wang X, Sun Y, Dong Y, Zhou J, et al. Tumor-associated CD8(+)T cell tolerance induced by erythroid progenitor cells. Front Immunol. 2024;15:1381919. https:\/\/doi.org\/10.3389\/fimmu.2024.1381919.","journal-title":"Front Immunol"},{"issue":"8","key":"1011_CR135","doi-asserted-by":"publisher","first-page":"105038","DOI":"10.1016\/j.jbc.2023.105038","volume":"299","author":"I Griswold-Prenner","year":"2023","unstructured":"Griswold-Prenner I, Kashyap AK, Mazhar S, Hall ZW, Fazelinia H, Ischiropoulos H. Unveiling the human nitroproteome: protein tyrosine nitration in cell signaling and cancer. J Biol Chem. 2023;299(8):105038. https:\/\/doi.org\/10.1016\/j.jbc.2023.105038.","journal-title":"J Biol Chem"},{"key":"1011_CR136","doi-asserted-by":"publisher","first-page":"1440269","DOI":"10.3389\/fimmu.2024.1440269","volume":"15","author":"Y Grobben","year":"2024","unstructured":"Grobben Y. Targeting amino acid-metabolizing enzymes for cancer immunotherapy. Front Immunol. 2024;15:1440269. https:\/\/doi.org\/10.3389\/fimmu.2024.1440269.","journal-title":"Front Immunol"},{"key":"1011_CR137","doi-asserted-by":"publisher","first-page":"1199233","DOI":"10.3389\/fimmu.2023.1199233","volume":"14","author":"P Shu","year":"2023","unstructured":"Shu P, Liang H, Zhang J, Lin Y, Chen W, Zhang D. Reactive oxygen species formation and its effect on CD4(+) T cell-mediated inflammation. Front Immunol. 2023;14:1199233. https:\/\/doi.org\/10.3389\/fimmu.2023.1199233.","journal-title":"Front Immunol"},{"issue":"5","key":"1011_CR138","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, et al. LDHA-Associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell MetabCell Metab. 2016;24(5):657\u201371. https:\/\/doi.org\/10.1016\/j.cmet.2016.08.011.","journal-title":"Cell MetabCell Metab"},{"key":"1011_CR139","doi-asserted-by":"publisher","unstructured":"Haas R, Smith J, Rocher-Ros V, Nadkarni S, Montero-Melendez T, D\u2019acquisto F, et al. Lactate regulates metabolic and pro-inflammatory circuits in control of T cell migration and effector functions. PLoS Biol. 2015;13(7):e1002202. https:\/\/doi.org\/10.1371\/journal.pbio.1002202.","DOI":"10.1371\/journal.pbio.1002202"},{"issue":"8","key":"1011_CR140","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.cmet.2022.06.008","volume":"34","author":"I Elia","year":"2022","unstructured":"Elia I, Rowe JH, Johnson S, Joshi S, Notarangelo G, Kurmi K, et al. Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8(+) T cells. Cell MetabCell Metab. 2022;34(8):1137\u201350.e1136. https:\/\/doi.org\/10.1016\/j.cmet.2022.06.008.","journal-title":"Cell MetabCell Metab"},{"key":"1011_CR141","doi-asserted-by":"publisher","first-page":"1492050","DOI":"10.3389\/fimmu.2024.1492050","volume":"15","author":"M Jiang","year":"2024","unstructured":"Jiang M, Wang Y, Zhao X, Yu J. From metabolic byproduct to immune modulator: the role of lactate in tumor immune escape. Front Immunol. 2024;15:1492050. https:\/\/doi.org\/10.3389\/fimmu.2024.1492050.","journal-title":"Front Immunol"},{"key":"1011_CR142","doi-asserted-by":"publisher","first-page":"1563303","DOI":"10.3389\/fimmu.2025.1563303","volume":"16","author":"XY Gu","year":"2025","unstructured":"Gu XY, Yang JL, Lai R, Zhou ZJ, Tang D, Hu L, et al. Impact of lactate on immune cell function in the tumor microenvironment: mechanisms and therapeutic perspectives. Front Immunol. 2025;16:1563303. https:\/\/doi.org\/10.3389\/fimmu.2025.1563303.","journal-title":"Front Immunol"},{"issue":"5","key":"1011_CR143","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211(5):781\u201390. https:\/\/doi.org\/10.1084\/jem.20131916.","journal-title":"J Exp Med"},{"issue":"7779","key":"1011_CR144","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","volume":"574","author":"RJ Johnston","year":"2019","unstructured":"Johnston RJ, Su LJ, Pinckney J, Critton D, Boyer E, Krishnakumar A, et al. VISTA is an acidic pH-selective ligand for PSGL-1. Nature. 2019;574(7779):565\u201370. https:\/\/doi.org\/10.1038\/s41586-019-1674-5.","journal-title":"Nature"},{"key":"1011_CR145","doi-asserted-by":"publisher","unstructured":"ElTanbouly MA, Zhao Y, Nowak E, Li J, Schaafsma E, Le Mercier I, et al. VISTA is a checkpoint regulator for na\u00efve T cell quiescence and peripheral tolerance. Sci (New York, N.Y.). 2020;367(6475). https:\/\/doi.org\/10.1126\/science.aay0524.","DOI":"10.1126\/science.aay0524"},{"issue":"1","key":"1011_CR146","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","volume":"12","author":"R Yang","year":"2021","unstructured":"Yang R, Sun L, Li CF, Wang YH, Yao J, Li H, et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun. 2021;12(1):832. https:\/\/doi.org\/10.1038\/s41467-021-21099-2.","journal-title":"Nat Commun"},{"key":"1011_CR147","doi-asserted-by":"publisher","first-page":"114646","DOI":"10.1016\/j.biopha.2023.114646","volume":"162","author":"K Mortezaee","year":"2023","unstructured":"Mortezaee K, Majidpoor J, Kharazinejad E. The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy. Biomed Pharmacother. 2023;162:114646. https:\/\/doi.org\/10.1016\/j.biopha.2023.114646.","journal-title":"Biomed Pharmacother"},{"issue":"6332","key":"1011_CR148","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aaf1292","volume":"355","author":"E Hui","year":"2017","unstructured":"Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, et al. T cell costimulatory receptor CD28 is a primary target for PD-1\u2013mediated inhibition. Sci (New York, N.Y.). 2017;355(6332):1428\u201333. https:\/\/doi.org\/10.1126\/science.aaf1292.","journal-title":"Sci (New York, N.Y.)"},{"issue":"1","key":"1011_CR149","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.1038\/ncomms7692","volume":"6","author":"N Patsoukis","year":"2015","unstructured":"Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015;6(1):6692. https:\/\/doi.org\/10.1038\/ncomms7692.","journal-title":"Nat Commun"},{"issue":"7749","key":"1011_CR150","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen J, L\u00f3pez-Moyado IF, Seo H, Lio C-WJ, Hempleman LJ, Sekiya T, et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019;567(7749):530\u201334. https:\/\/doi.org\/10.1038\/s41586-019-0985-x.","journal-title":"Nature"},{"issue":"6316","key":"1011_CR151","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.aaf2807","volume":"354","author":"KE Pauken","year":"2016","unstructured":"Pauken KE, Sammons MA, Odorizzi PM, Manne S, Godec J, Khan O, et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Sci (New York, N.Y.). 2016;354(6316):1160\u201365. https:\/\/doi.org\/10.1126\/science.aaf2807.","journal-title":"Sci (New York, N.Y.)"},{"issue":"6","key":"1011_CR152","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/s41590-022-01224-z","volume":"23","author":"JA Belk","year":"2022","unstructured":"Belk JA, Daniel B, Satpathy AT. Epigenetic regulation of T cell exhaustion. Nat Immunol. 2022;23(6):848\u201360. https:\/\/doi.org\/10.1038\/s41590-022-01224-z.","journal-title":"Nat Immunol"},{"issue":"1","key":"1011_CR153","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/s1074-7613(03)00174-2","volume":"19","author":"F Geissmann","year":"2003","unstructured":"Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003;19(1):71\u201382. https:\/\/doi.org\/10.1016\/s1074-7613(03)00174-2.","journal-title":"Immunity"},{"key":"1011_CR154","doi-asserted-by":"publisher","unstructured":"Ingersoll MA, Spanbroek R, Lottaz C, Gautier EL, Frankenberger M, Hoffmann R, et al. Comparison of gene expression profiles between human and mouse monocyte subsets. Blood. 2010;115(3):e10\u201319. https:\/\/doi.org\/10.1182\/blood-2009-07-235028.","DOI":"10.1182\/blood-2009-07-235028"},{"issue":"7355","key":"1011_CR155","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature10138","volume":"475","author":"BZ Qian","year":"2011","unstructured":"Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222\u201325. https:\/\/doi.org\/10.1038\/nature10138.","journal-title":"Nature"},{"issue":"5","key":"1011_CR156","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/s1470-2045(16)00078-4","volume":"17","author":"TM Nywening","year":"2016","unstructured":"Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17(5):651\u201362. https:\/\/doi.org\/10.1016\/s1470-2045(16)00078-4.","journal-title":"Lancet Oncol"},{"issue":"13","key":"1011_CR157","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1158\/1078-0432.Ccr-13-0525","volume":"19","author":"DE Sanford","year":"2013","unstructured":"Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2\/CCR2 axis. Clin Cancer Res: Off J Am Assoc Cancer Res. 2013;19(13):3404\u201315. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-0525.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"1011_CR158","doi-asserted-by":"publisher","unstructured":"Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med. 2014;6(237):237ra267. https:\/\/doi.org\/10.1126\/scitranslmed.3007974.","DOI":"10.1126\/scitranslmed.3007974"},{"issue":"3","key":"1011_CR159","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1593\/neo.07976","volume":"10","author":"LA Begley","year":"2008","unstructured":"Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, et al. CXCL5 promotes prostate cancer progression. Neoplasia (New York, N.Y.). 2008;10(3):244\u201354. https:\/\/doi.org\/10.1593\/neo.07976.","journal-title":"Neoplasia (New York, N.Y.)"},{"issue":"6","key":"1011_CR160","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1136\/gutjnl-2017-313738","volume":"67","author":"TM Nywening","year":"2018","unstructured":"Nywening TM, Belt BA, Cullinan DR, Panni RZ, Han BJ, Sanford DE, et al. Targeting both tumour-associated CXCR2(+) neutrophils and CCR2(+) macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut. 2018;67(6):1112\u201323. https:\/\/doi.org\/10.1136\/gutjnl-2017-313738.","journal-title":"Gut"},{"issue":"10","key":"1011_CR161","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.1172\/jci137110","volume":"130","author":"E Loeuillard","year":"2020","unstructured":"Loeuillard E, Yang J, Buckarma E, Wang J, Liu Y, Conboy C, et al. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J Clin InvestJournal Clin Investigation. 2020;130(10):5380\u201396. https:\/\/doi.org\/10.1172\/jci137110.","journal-title":"J Clin InvestJournal Clin Investigation"},{"key":"1011_CR162","doi-asserted-by":"publisher","first-page":"1517959","DOI":"10.3389\/fimmu.2025.1517959","volume":"16","author":"J Yu","year":"2025","unstructured":"Yu J, Fu L, Wu R, Che L, Liu G, Ran Q, et al. Immunocytes in the tumor microenvironment: recent updates and interconnections. Front Immunol. 2025;16:1517959. https:\/\/doi.org\/10.3389\/fimmu.2025.1517959.","journal-title":"Front Immunol"},{"issue":"8","key":"1011_CR163","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/1535-7163.Mct-20-0591","volume":"20","author":"T Fujiwara","year":"2021","unstructured":"Fujiwara T, Yakoub MA, Chandler A, Christ AB, Yang G, Ouerfelli O, et al. CSF1\/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated Macrophages and stimulates T-cell infiltration in the sarcoma microenvironment. Mol Cancer Ther. 2021;20(8):1388\u201399. https:\/\/doi.org\/10.1158\/1535-7163.Mct-20-0591.","journal-title":"Mol Cancer Ther"},{"key":"1011_CR164","doi-asserted-by":"publisher","unstructured":"Gharzeddine K, Gonzalez Prieto CG, Malier M, Hennot C, Grespan R, Yamaryo-Bott\u00e9 Y, et al. Metabolic reprogramming of hypoxic tumor-associated macrophages through CSF-1R targeting favors treatment efficiency in colorectal cancers. J Immunother Cancer. 2024;12(9):e009602. https:\/\/doi.org\/10.1136\/jitc-2024-009602.","DOI":"10.1136\/jitc-2024-009602"},{"issue":"5","key":"1011_CR165","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.ccell.2017.10.005","volume":"32","author":"V Kumar","year":"2017","unstructured":"Kumar V, Donthireddy L, Marvel D, Condamine T, Wang F, Lavilla-Alonso S, et al. Cancer-associated fibroblasts neutralize the Anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors. Cancer Cell. 2017;32(5):654\u201368.e5. https:\/\/doi.org\/10.1016\/j.ccell.2017.10.005.","journal-title":"Cancer Cell"},{"key":"1011_CR166","doi-asserted-by":"publisher","unstructured":"Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT, et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Sci (New York, N.Y.). 2016;352(6288):aad3018. https:\/\/doi.org\/10.1126\/science.aad3018.","DOI":"10.1126\/science.aad3018"},{"key":"1011_CR167","doi-asserted-by":"publisher","first-page":"1550893","DOI":"10.3389\/fimmu.2025.1550893","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang X, Wang Y, Yang L, Zhang Y, Yang L. TREM2(+) macrophages: a key role in disease development. Front Immunol. 2025;16:1550893. https:\/\/doi.org\/10.3389\/fimmu.2025.1550893.","journal-title":"Front Immunol"},{"issue":"7629","key":"1011_CR168","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature19834","volume":"539","author":"MM Kaneda","year":"2016","unstructured":"Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, et al. PI3K\u03b3 is a molecular switch that controls immune suppression. Nature. 2016;539(7629):437\u201342. https:\/\/doi.org\/10.1038\/nature19834.","journal-title":"Nature"},{"issue":"7629","key":"1011_CR169","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature20554","volume":"539","author":"OD De Henau","year":"2016","unstructured":"De Henau OD, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells. Nature. 2016;539(7629):443\u201347. https:\/\/doi.org\/10.1038\/nature20554.","journal-title":"Nature"},{"issue":"4","key":"1011_CR170","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","volume":"182","author":"M Molgora","year":"2020","unstructured":"Molgora M, Esaulova E, Vermi W, Hou J, Chen Y, Luo J, et al. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy. Cell. 2020;182(4):886\u2013900.e17. https:\/\/doi.org\/10.1016\/j.cell.2020.07.013.","journal-title":"Cell"},{"issue":"11","key":"1011_CR171","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21(11):799\u2013820. https:\/\/doi.org\/10.1038\/s41573-022-00520-5.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"1011_CR172","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10637-024-01419-1","volume":"42","author":"KE Beckermann","year":"2024","unstructured":"Beckermann KE, Patnaik A, Winer I, Tan W, Bashir B, Kyriakopoulos CE, et al. A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma. Invest New Drugs. 2024;42(2):179\u201384. https:\/\/doi.org\/10.1007\/s10637-024-01419-1.","journal-title":"Invest New Drugs"},{"key":"1011_CR173","doi-asserted-by":"publisher","unstructured":"Redavid AR, Cifaldi L, Bei R, De Billy ED, Fruci D. Targeting macrophage-driven NK cell immunosuppression to improve cancer immunotherapy. J Immunother Cancer. 2026;14(6):e014840. https:\/\/doi.org\/10.1136\/jitc-2026-014840.","DOI":"10.1136\/jitc-2026-014840"},{"issue":"5","key":"1011_CR174","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","volume":"52","author":"MEW Logtenberg","year":"2020","unstructured":"Logtenberg MEW, Scheeren FA, Schumacher TN. The CD47-SIRP\u03b1 immune checkpoint. Immunity. 2020;52(5):742\u201352. https:\/\/doi.org\/10.1016\/j.immuni.2020.04.011.","journal-title":"Immunity"},{"issue":"5","key":"1011_CR175","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/0008-5472.Can-20-2990","volume":"81","author":"NR Anderson","year":"2021","unstructured":"Anderson NR, Minutolo NG, Gill S, Klichinsky M. Macrophage-based approaches for cancer immunotherapy. Cancer Res. 2021;81(5):1201\u201308. https:\/\/doi.org\/10.1158\/0008-5472.Can-20-2990.","journal-title":"Cancer Res"},{"issue":"4","key":"1011_CR176","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.cell.2017.12.026","volume":"172","author":"MF Tavazoie","year":"2018","unstructured":"Tavazoie MF, Pollack I, Tanqueco R, Ostendorf BN, Reis BS, Gonsalves FC, et al. LXR\/ApoE activation restricts innate immune suppression in cancer. Cell. 2018;172(4):825\u201340.e18. https:\/\/doi.org\/10.1016\/j.cell.2017.12.026.","journal-title":"Cell"},{"issue":"12","key":"1011_CR177","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.it.2016.09.001","volume":"37","author":"MB Fessler","year":"2016","unstructured":"Fessler MB. The intracellular cholesterol landscape: dynamic integrator of the immune response. Trends Immunol. 2016;37(12):819\u201330. https:\/\/doi.org\/10.1016\/j.it.2016.09.001.","journal-title":"Trends Immunol"},{"issue":"1","key":"1011_CR178","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40425-017-0308-4","volume":"5","author":"SM Steggerda","year":"2017","unstructured":"Steggerda SM, Bennett MK, Chen J, Emberley E, Huang T, Janes JR, et al. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J. Immunother Cancer. 2017;5(1):101. https:\/\/doi.org\/10.1186\/s40425-017-0308-4.","journal-title":"J. Immunother Cancer"},{"issue":"5","key":"1011_CR179","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","volume":"18","author":"M Platten","year":"2019","unstructured":"Platten M, Nollen EAA, R\u00f6hrig UF, Fallarino F, Opitz CA. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019;18(5):379\u2013401. https:\/\/doi.org\/10.1038\/s41573-019-0016-5.","journal-title":"Nat Rev Drug Discov"},{"key":"1011_CR180","doi-asserted-by":"publisher","first-page":"807271","DOI":"10.3389\/fimmu.2022.807271","volume":"13","author":"F Peyraud","year":"2022","unstructured":"Peyraud F, Guegan JP, Bodet D, Cousin S, Bessede A, Italiano A. Targeting tryptophan catabolism in cancer immunotherapy Era: challenges and perspectives. Front Immunol. 2022;13:807271. https:\/\/doi.org\/10.3389\/fimmu.2022.807271.","journal-title":"Front Immunol"},{"issue":"5","key":"1011_CR181","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/ijc.34750","volume":"154","author":"J Xia","year":"2024","unstructured":"Xia J, Zhang Z, Huang Y, Wang Y, Liu G. Regulation of neutrophil extracellular traps in cancer. Intl J Cancer. 2024;154(5):773\u201385. https:\/\/doi.org\/10.1002\/ijc.34750.","journal-title":"Intl J Cancer"},{"key":"1011_CR182","doi-asserted-by":"publisher","first-page":"1135086","DOI":"10.3389\/fimmu.2023.1135086","volume":"14","author":"M Yan","year":"2023","unstructured":"Yan M, Gu Y, Sun H, Ge Q. Neutrophil extracellular traps in tumor progression and immunotherapy. Front Immunol. 2023;14:1135086. https:\/\/doi.org\/10.3389\/fimmu.2023.1135086.","journal-title":"Front Immunol"},{"key":"1011_CR183","doi-asserted-by":"publisher","first-page":"1666261","DOI":"10.3389\/fimmu.2025.1666261","volume":"16","author":"ML Morawiec","year":"2025","unstructured":"Morawiec ML, Kubina R, Jab\u0142o\u0144ska E, Ratajczak-Wrona W, St\u0119pie\u0144 S, Go\u0142\u0119bski M, et al. Nets - as predictors and targets of supportive therapy for cancer treatment. Front Immunol. 2025;16:1666261. https:\/\/doi.org\/10.3389\/fimmu.2025.1666261.","journal-title":"Front Immunol"},{"issue":"1","key":"1011_CR184","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41556-018-0250-9","volume":"21","author":"M Mathieu","year":"2019","unstructured":"Mathieu M, Martin-Jaular L, Lavieu G, Th\u00e9ry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol. 2019;21(1):9\u201317. https:\/\/doi.org\/10.1038\/s41556-018-0250-9.","journal-title":"Nat Cell Biol"},{"issue":"2","key":"1011_CR185","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1172\/jci40483","volume":"120","author":"F Chalmin","year":"2010","unstructured":"Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 2010;120(2):457\u201371. https:\/\/doi.org\/10.1172\/jci40483.","journal-title":"J Clin Invest"},{"issue":"18","key":"1011_CR186","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1158\/0008-5472.Can-19-0053","volume":"79","author":"V Fleming","year":"2019","unstructured":"Fleming V, Hu X, Weller C, Weber R, Groth C, Riester Z, et al. Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling. Cancer Res. 2019;79(18):4715\u201328. https:\/\/doi.org\/10.1158\/0008-5472.Can-19-0053.","journal-title":"Cancer Res"},{"issue":"10","key":"1011_CR187","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.cmet.2021.09.002","volume":"33","author":"SM Morrissey","year":"2021","unstructured":"Morrissey SM, Zhang F, Ding C, Montoya-Durango DE, Hu X, Yang C, et al. Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. Cell Metab. 2021;33(10):2040\u201358.e10. https:\/\/doi.org\/10.1016\/j.cmet.2021.09.002.","journal-title":"Cell Metab"},{"issue":"2","key":"1011_CR188","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","volume":"177","author":"M Poggio","year":"2019","unstructured":"Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019;177(2):414\u201327.e13. https:\/\/doi.org\/10.1016\/j.cell.2019.02.016.","journal-title":"Cell"},{"key":"1011_CR189","doi-asserted-by":"publisher","first-page":"1742654","DOI":"10.3389\/fimmu.2025.1742654","volume":"16","author":"Y Dai","year":"2026","unstructured":"Dai Y, Luo X, Zhang L, Yan J. Roles of immunosuppressive myeloid states in colorectal cancer checkpoint inhibitor non-response: single-cell and spatial proteomics, and reprogramming approaches. Front Immunol. 2026;16:1742654. https:\/\/doi.org\/10.3389\/fimmu.2025.1742654.","journal-title":"Front Immunol"},{"key":"1011_CR190","doi-asserted-by":"publisher","first-page":"1773233","DOI":"10.3389\/fimmu.2026.1773233","volume":"17","author":"Z Hong","year":"2026","unstructured":"Hong Z, Wu Y, Liu W, Li D, Xu J. Metabolic reprogramming in tumor-associated cells of hematologic malignancies: mechanisms, crosstalk networks, and therapeutic implications in the tumor microenvironment. Front Immunol. 2026;17:1773233. https:\/\/doi.org\/10.3389\/fimmu.2026.1773233.","journal-title":"Front Immunol"},{"key":"1011_CR191","doi-asserted-by":"publisher","first-page":"1742855","DOI":"10.3389\/fimmu.2025.1742855","volume":"16","author":"M Li","year":"2026","unstructured":"Li M, Wang T, Zhang Z, Dongye Y. Metabolic reprogramming in the post-metastatic tumor microenvironment: multi-omics insights into determinants of immunotherapy response. Front Immunol. 2026;16:1742855. https:\/\/doi.org\/10.3389\/fimmu.2025.1742855.","journal-title":"Front Immunol"},{"key":"1011_CR192","doi-asserted-by":"publisher","first-page":"1697675","DOI":"10.3389\/fimmu.2025.1697675","volume":"16","author":"L Zhou","year":"2026","unstructured":"Zhou L, Zhang W, Liu Z, Xie Y, Jiang K. Immune cell metabolic reprogramming in hepatocellular carcinoma: mechanisms, tumor microenvironment, and future immunotherapeutic directions. Front Immunol. 2026;16:1697675. https:\/\/doi.org\/10.3389\/fimmu.2025.1697675.","journal-title":"Front Immunol"},{"key":"1011_CR193","doi-asserted-by":"publisher","first-page":"759015","DOI":"10.3389\/fonc.2021.759015","volume":"11","author":"Y Xu","year":"2021","unstructured":"Xu Y, He L, Fu Q, Hu J. Metabolic reprogramming in the tumor microenvironment with immunocytes and immune checkpoints. Front Oncol. 2021;11:759015. https:\/\/doi.org\/10.3389\/fonc.2021.759015.","journal-title":"Front Oncol"},{"issue":"4","key":"1011_CR194","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","volume":"35","author":"W Liao","year":"2019","unstructured":"Liao W, Overman MJ, Boutin AT, Shang X, Zhao D, Dey P, et al. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell. 2019;35(4):559\u201372.e7. https:\/\/doi.org\/10.1016\/j.ccell.2019.02.008.","journal-title":"Cancer Cell"},{"issue":"1","key":"1011_CR195","doi-asserted-by":"publisher","first-page":"5421","DOI":"10.1038\/s41467-019-13204-3","volume":"10","author":"L Shi","year":"2019","unstructured":"Shi L, Wang J, Ding N, Zhang Y, Zhu Y, Dong S, et al. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. Nat Commun. 2019;10(1):5421. https:\/\/doi.org\/10.1038\/s41467-019-13204-3.","journal-title":"Nat Commun"},{"issue":"1","key":"1011_CR196","doi-asserted-by":"publisher","first-page":"2338965","DOI":"10.1080\/2162402x.2024.2338965","volume":"13","author":"A Pant","year":"2024","unstructured":"Pant A, Hwa-Lin Bergsneider BH-L, Srivastava S, Kim T, Jain A, Bom S, et al. CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-PD-1 therapy. Oncoimmunology. 2024;13(1):2338965. https:\/\/doi.org\/10.1080\/2162402x.2024.2338965.","journal-title":"Oncoimmunology"},{"issue":"4","key":"1011_CR197","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41568-022-00547-1","volume":"23","author":"L Cassetta","year":"2023","unstructured":"Cassetta L, Pollard JW. A timeline of tumour-associated macrophage biology. Nat Rev Cancer. 2023;23(4):238\u201357. https:\/\/doi.org\/10.1038\/s41568-022-00547-1.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1011_CR198","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s43556-025-00396-y","volume":"6","author":"W Tang","year":"2025","unstructured":"Tang W, Wang X, Han B, Jiang SH, Cao H. Tumor-associated macrophages in cancer: from mechanisms to application. Mol Biomed. 2025;6(1):145. https:\/\/doi.org\/10.1186\/s43556-025-00396-y.","journal-title":"Mol Biomed"},{"issue":"7647","key":"1011_CR199","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nature21676","volume":"543","author":"X Lu","year":"2017","unstructured":"Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017;543(7647):728\u201332. https:\/\/doi.org\/10.1038\/nature21676.","journal-title":"Nature"},{"issue":"5","key":"1011_CR200","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","volume":"26","author":"KA Schalper","year":"2020","unstructured":"Schalper KA, Carleton M, Zhou M, Chen T, Feng Y, Huang SP, et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med. 2020;26(5):688\u201392. https:\/\/doi.org\/10.1038\/s41591-020-0856-x.","journal-title":"Nat Med"},{"issue":"5","key":"1011_CR201","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41591-020-0860-1","volume":"26","author":"KC Yuen","year":"2020","unstructured":"Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat Med. 2020;26(5):693\u201398. https:\/\/doi.org\/10.1038\/s41591-020-0860-1.","journal-title":"Nat Med"},{"issue":"4","key":"1011_CR202","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.Cd-20-1680","volume":"11","author":"P Sharma","year":"2021","unstructured":"Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, et al. The Next Decade of immune checkpoint therapy. Cancer Discov. 2021;11(4):838\u201357. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-1680.","journal-title":"Cancer Discov"},{"issue":"1","key":"1011_CR203","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","volume":"19","author":"L Kraehenbuehl","year":"2022","unstructured":"Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol. 2022;19(1):37\u201350. https:\/\/doi.org\/10.1038\/s41571-021-00552-7.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1011_CR204","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10637-023-01410-2","volume":"42","author":"AJ Armstrong","year":"2024","unstructured":"Armstrong AJ, Geva R, Chung HC, Lemech C, Miller W, Hansen ARH Jr, et al. CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial. Invest New Drugs. 2024;42(1):145\u201359. https:\/\/doi.org\/10.1007\/s10637-023-01410-2.","journal-title":"Invest New Drugs"},{"issue":"7","key":"1011_CR205","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrc.2016.54","volume":"16","author":"C Engblom","year":"2016","unstructured":"Engblom C, Pfirschke C, Pittet MJ. The role of myeloid cells in cancer therapies. Nat Rev Cancer. 2016;16(7):447\u201362. https:\/\/doi.org\/10.1038\/nrc.2016.54.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1011_CR206","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.Cd-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jord\u0101o MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11(4):933\u201359. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-1808.","journal-title":"Cancer Discov"},{"issue":"8","key":"1011_CR207","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/nm.2172","volume":"16","author":"DL Herber","year":"2010","unstructured":"Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med. 2010;16(8):880\u201386. https:\/\/doi.org\/10.1038\/nm.2172.","journal-title":"Nat Med"},{"issue":"1","key":"1011_CR208","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/s41467-017-02186-9","volume":"8","author":"F Veglia","year":"2017","unstructured":"Veglia F, Tyurin VA, Mohammadyani D, Blasi M, Duperret EK, Donthireddy L, et al. Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer. Nat Commun. 2017;8(1):2122. https:\/\/doi.org\/10.1038\/s41467-017-02186-9.","journal-title":"Nat Commun"},{"issue":"7","key":"1011_CR209","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.cell.2020.11.009","volume":"183","author":"AE Ringel","year":"2020","unstructured":"Ringel AE, Drijvers JM, Baker GJ, Catozzi A, Garc\u00eda-Ca\u00f1averas JC, Gassaway BM, et al. Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity. Cell. 2020;183(7):1848\u201366.e26. https:\/\/doi.org\/10.1016\/j.cell.2020.11.009.","journal-title":"Cell"},{"issue":"1","key":"1011_CR210","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12967-020-02618-z","volume":"18","author":"I Hwang","year":"2020","unstructured":"Hwang I, Kim JW, Ylaya K, Chung EJ, Kitano H, Perry C, et al. Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients. J Transl Med. 2020;18(1):443. https:\/\/doi.org\/10.1186\/s12967-020-02618-z.","journal-title":"J Transl Med"},{"key":"1011_CR211","doi-asserted-by":"publisher","first-page":"101055","DOI":"10.1016\/j.plipres.2020.101055","volume":"80","author":"KC Corn","year":"2020","unstructured":"Corn KC, Windham MA, Rafat M. Lipids in the tumor microenvironment: from cancer progression to treatment. Prog Lipid Res. 2020;80:101055. https:\/\/doi.org\/10.1016\/j.plipres.2020.101055.","journal-title":"Prog Lipid Res"},{"issue":"1","key":"1011_CR212","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s42255-020-00317-z","volume":"3","author":"I Elia","year":"2021","unstructured":"Elia I, Haigis MC. Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nat Metab. 2021;3(1):21\u201332. https:\/\/doi.org\/10.1038\/s42255-020-00317-z.","journal-title":"Nat Metab"},{"issue":"2","key":"1011_CR213","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","volume":"40","author":"S Kumagai","year":"2022","unstructured":"Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. 2022;40(2):201\u201318.e9. https:\/\/doi.org\/10.1016\/j.ccell.2022.01.001.","journal-title":"Cancer Cell"},{"issue":"9","key":"1011_CR214","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41568-020-0273-y","volume":"20","author":"RD Leone","year":"2020","unstructured":"Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020;20(9):516\u201331. https:\/\/doi.org\/10.1038\/s41568-020-0273-y.","journal-title":"Nat Rev Cancer"},{"key":"1011_CR215","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3389\/fimmu.2020.00938","volume":"11","author":"TM Grzywa","year":"2020","unstructured":"Grzywa TM, Sosnowska A, Matryba P, Rydzynska Z, Jasinski M, Nowis D, et al. Myeloid cell-derived arginase in cancer immune response. Front Immunol. 2020;11:938. https:\/\/doi.org\/10.3389\/fimmu.2020.00938.","journal-title":"Front Immunol"},{"issue":"7","key":"1011_CR216","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1084\/jem.20130066","volume":"210","author":"RB Holmgaard","year":"2013","unstructured":"Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013;210(7):1389\u2013402. https:\/\/doi.org\/10.1084\/jem.20130066.","journal-title":"J Exp Med"},{"issue":"1","key":"1011_CR217","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40425-019-0504-5","volume":"7","author":"JJ Miret","year":"2019","unstructured":"Miret JJ, Kirschmeier P, Koyama S, Zhu M, Li YY, Naito Y, et al. Suppression of myeloid cell arginase activity leads to Therapeutic response in a NSCLC mouse Model by activating anti-tumor immunity. J. Immunother Cancer. 2019;7(1):32. https:\/\/doi.org\/10.1186\/s40425-019-0504-5.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1011_CR218","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.molcel.2020.05.034","volume":"78","author":"JE Bader","year":"2020","unstructured":"Bader JE, Voss K, Rathmell JC. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. Mol Cell. 2020;78(6):1019\u201333. https:\/\/doi.org\/10.1016\/j.molcel.2020.05.034.","journal-title":"Mol Cell"},{"issue":"8","key":"1011_CR219","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/s1470-2045(19)30274-8","volume":"20","author":"GV Long","year":"2019","unstructured":"Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019;20(8):1083\u201397. https:\/\/doi.org\/10.1016\/s1470-2045(19)30274-8.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1011_CR220","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","volume":"22","author":"M Philip","year":"2022","unstructured":"Philip M, Schietinger A. CD8(+) T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2022;22(4):209\u201323. https:\/\/doi.org\/10.1038\/s41577-021-00574-3.","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"1011_CR221","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s41590-020-0725-2","volume":"21","author":"SA Vardhana","year":"2020","unstructured":"Vardhana SA, Hwee MA, Berisa M, Wells DK, Yost KE, King B, et al. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat Immunol. 2020;21(9):1022\u201333. https:\/\/doi.org\/10.1038\/s41590-020-0725-2.","journal-title":"Nat Immunol"},{"issue":"2","key":"1011_CR222","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","volume":"22","author":"NE Scharping","year":"2021","unstructured":"Scharping NE, Rivadeneira DB, Menk AV, Vignali PDA, Ford BR, Rittenhouse NL, et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol. 2021;22(2):205\u201315. https:\/\/doi.org\/10.1038\/s41590-020-00834-9.","journal-title":"Nat Immunol"},{"issue":"11","key":"1011_CR223","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41577-021-00537-8","volume":"21","author":"M Reina-Campos","year":"2021","unstructured":"Reina-Campos M, Scharping NE, Goldrath AW. CD8(+) T cell metabolism in infection and cancer. Nat Rev Immunol. 2021;21(11):718\u201338. https:\/\/doi.org\/10.1038\/s41577-021-00537-8.","journal-title":"Nat Rev Immunol"},{"issue":"7727","key":"1011_CR224","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41586-018-0597-x","volume":"562","author":"M Song","year":"2018","unstructured":"Song M, Sandoval TA, Chae CS, Chopra S, Tan C, Rutkowski MR, et al. IRE1\u03b1\u2013XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. Nature. 2018;562(7727):423\u201328. https:\/\/doi.org\/10.1038\/s41586-018-0597-x.","journal-title":"Nature"},{"issue":"10","key":"1011_CR225","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s42255-020-00280-9","volume":"2","author":"F Franco","year":"2020","unstructured":"Franco F, Jaccard A, Romero P, Yu YR, Ho PC. Metabolic and epigenetic regulation of T-cell exhaustion. Nat Metab. 2020;2(10):1001\u201312. https:\/\/doi.org\/10.1038\/s42255-020-00280-9.","journal-title":"Nat Metab"},{"issue":"12","key":"1011_CR226","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19(12):775\u201390. https:\/\/doi.org\/10.1038\/s41571-022-00689-z.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"1011_CR227","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ccell.2022.06.001","volume":"40","author":"JA Belk","year":"2022","unstructured":"Belk JA, Yao W, Ly N, Freitas KA, Chen YT, Shi Q, et al. Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Cancer Cell. 2022;40(7):768\u201386.e7. https:\/\/doi.org\/10.1016\/j.ccell.2022.06.001.","journal-title":"Cancer Cell"},{"issue":"6332","key":"1011_CR228","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.aaf0683","volume":"355","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, et al. Rescue of exhausted CD8 T cells by PD-1\u2013targeted therapies is CD28-dependent. Sci (New York, N.Y.). 2017;355(6332):1423\u201327. https:\/\/doi.org\/10.1126\/science.aaf0683.","journal-title":"Sci (New York, N.Y.)"},{"issue":"7755","key":"1011_CR229","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","volume":"569","author":"W Wang","year":"2019","unstructured":"Wang W, Green M, Choi JE, Gij\u00f3n M, Kennedy PD, Johnson JK, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270\u201374. https:\/\/doi.org\/10.1038\/s41586-019-1170-y.","journal-title":"Nature"},{"issue":"4","key":"1011_CR230","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ccell.2022.02.003","volume":"40","author":"P Liao","year":"2022","unstructured":"Liao P, Wang W, Wang W, Kryczek I, Li X, Bian Y, et al. CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell. 2022;40(4):365\u201378.e366. https:\/\/doi.org\/10.1016\/j.ccell.2022.02.003.","journal-title":"Cancer Cell"},{"issue":"7","key":"1011_CR231","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41568-019-0149-1","volume":"19","author":"JPF Friedmann Angeli","year":"2019","unstructured":"Friedmann Angeli JPF, Krysko DV, Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer. 2019;19(7):405\u201314. https:\/\/doi.org\/10.1038\/s41568-019-0149-1.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1011_CR232","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18(5):280\u201396. https:\/\/doi.org\/10.1038\/s41571-020-00462-0.","journal-title":"Nat Rev Clin Oncol"},{"key":"1011_CR233","doi-asserted-by":"publisher","unstructured":"Efimova I, Catanzaro E, Van der Meeren LV, Turubanova VD, Hammad H, Mishchenko TA, et al. Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J Immunother Cancer. 2020;8(2):e001369. https:\/\/doi.org\/10.1136\/jitc-2020-001369.","DOI":"10.1136\/jitc-2020-001369"},{"issue":"9","key":"1011_CR234","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.molmed.2021.06.014","volume":"27","author":"H Xu","year":"2021","unstructured":"Xu H, Ye D, Ren M, Zhang H, Bi F. Ferroptosis in the tumor microenvironment: perspectives for immunotherapy. Trends Mol Med. 2021;27(9):856\u201367. https:\/\/doi.org\/10.1016\/j.molmed.2021.06.014.","journal-title":"Trends Mol Med"},{"issue":"1","key":"1011_CR235","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-020-00946-7","volume":"13","author":"R Tang","year":"2020","unstructured":"Tang R, Xu J, Zhang B, Liu J, Liang C, Hua J, et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J Hematol Oncol. 2020;13(1):110. https:\/\/doi.org\/10.1186\/s13045-020-00946-7.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"1011_CR236","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/0008-5472.Can-09-3690","volume":"70","author":"J Vincent","year":"2010","unstructured":"Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell\u2013dependent antitumor immunity. Cancer Res. 2010;70(8):3052\u201361. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-3690.","journal-title":"Cancer Res"},{"issue":"6","key":"1011_CR237","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","volume":"28","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690\u2013714. https:\/\/doi.org\/10.1016\/j.ccell.2015.10.012.","journal-title":"Cancer Cell"},{"issue":"18","key":"1011_CR238","doi-asserted-by":"publisher","first-page":"6713","DOI":"10.1158\/1078-0432.Ccr-05-0883","volume":"11","author":"E Suzuki","year":"2005","unstructured":"Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic gr-1+\/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res: Off J Am Assoc Cancer Res. 2005;11(18):6713\u201321. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-05-0883.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"1","key":"1011_CR239","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","volume":"5","author":"MA Cannarile","year":"2017","unstructured":"Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, R\u00fcttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J. Immunother Cancer. 2017;5(1):53. https:\/\/doi.org\/10.1186\/s40425-017-0257-y.","journal-title":"J. Immunother Cancer"},{"key":"1011_CR240","doi-asserted-by":"publisher","unstructured":"Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Wald N, Martignier C, et al. T cell\u2013induced CSF1 promotes melanoma resistance to PD1 blockade. Sci Transl Med. 2018;10(436). https:\/\/doi.org\/10.1126\/scitranslmed.aan3311.","DOI":"10.1126\/scitranslmed.aan3311"},{"issue":"10197","key":"1011_CR241","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/s0140-6736(19)30764-0","volume":"394","author":"WD Tap","year":"2019","unstructured":"Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019;394(10197):478\u201387. https:\/\/doi.org\/10.1016\/s0140-6736(19)30764-0.","journal-title":"Lancet"},{"issue":"1","key":"1011_CR242","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Sig Transduct Target Ther. 2021;6(1):402. https:\/\/doi.org\/10.1038\/s41392-021-00791-1.","journal-title":"Sig Transduct Target Ther"},{"issue":"5","key":"1011_CR243","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"SR Woo","year":"2014","unstructured":"Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MK, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41(5):830\u201342. https:\/\/doi.org\/10.1016\/j.immuni.2014.10.017.","journal-title":"Immunity"},{"issue":"7","key":"1011_CR244","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","volume":"11","author":"L Corrales","year":"2015","unstructured":"Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015;11(7):1018\u201330. https:\/\/doi.org\/10.1016\/j.celrep.2015.04.031.","journal-title":"Cell Rep"},{"issue":"11","key":"1011_CR245","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1016\/j.celrep.2018.11.047","volume":"25","author":"KE Sivick","year":"2018","unstructured":"Sivick KE, Desbien AL, Glickman LH, Reiner GL, Corrales L, Surh NH, et al. Magnitude of therapeutic STING activation determines CD8(+) T cell-mediated anti-tumor immunity. Cell Rep. 2018;25(11):3074\u201385.e3075. https:\/\/doi.org\/10.1016\/j.celrep.2018.11.047.","journal-title":"Cell Rep"},{"issue":"10","key":"1011_CR246","doi-asserted-by":"publisher","first-page":"5328","DOI":"10.1128\/jvi.00037-14","volume":"88","author":"T Abe","year":"2014","unstructured":"Abe T, Barber GN. Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-\u03baB activation through TBK1. J Virol. 2014;88(10):5328\u201341. https:\/\/doi.org\/10.1128\/jvi.00037-14.","journal-title":"J Virol"},{"key":"1011_CR247","doi-asserted-by":"publisher","first-page":"1016870","DOI":"10.3389\/fimmu.2022.1016870","volume":"13","author":"L Xu","year":"2022","unstructured":"Xu L, Zhou C, Liang Y, Fan T, Zhang F, Chen X, et al. Epigenetic modifications in the accumulation and function of myeloid-derived suppressor cells. Front Immunol. 2022;13:1016870. https:\/\/doi.org\/10.3389\/fimmu.2022.1016870.","journal-title":"Front Immunol"},{"key":"1011_CR248","doi-asserted-by":"publisher","first-page":"781660","DOI":"10.3389\/fimmu.2022.781660","volume":"13","author":"AO Adeshakin","year":"2022","unstructured":"Adeshakin AO, Adeshakin FO, Yan D, Wan X. Regulating histone deacetylase signaling pathways of myeloid-derived suppressor cells enhanced T cell-based immunotherapy. Front Immunol. 2022;13:781660. https:\/\/doi.org\/10.3389\/fimmu.2022.781660.","journal-title":"Front Immunol"},{"issue":"1","key":"1011_CR249","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","volume":"6","author":"Z Duan","year":"2021","unstructured":"Duan Z, Luo Y. Targeting macrophages in cancer immunotherapy. Sig Transduct Target Ther. 2021;6(1):127. https:\/\/doi.org\/10.1038\/s41392-021-00506-6.","journal-title":"Sig Transduct Target Ther"},{"issue":"8","key":"1011_CR250","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38(8):947\u201353. https:\/\/doi.org\/10.1038\/s41587-020-0462-y.","journal-title":"Nat Biotechnol"},{"issue":"21","key":"1011_CR251","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309\u201337. https:\/\/doi.org\/10.1016\/j.cell.2021.09.020.","journal-title":"Cell"},{"issue":"18","key":"1011_CR252","doi-asserted-by":"publisher","first-page":"9299","DOI":"10.1158\/0008-5472.Can-06-1690","volume":"66","author":"N Mirza","year":"2006","unstructured":"Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006;66(18):9299\u2013307. https:\/\/doi.org\/10.1158\/0008-5472.Can-06-1690.","journal-title":"Cancer Res"},{"issue":"22","key":"1011_CR253","doi-asserted-by":"publisher","first-page":"11021","DOI":"10.1158\/0008-5472.Can-07-2593","volume":"67","author":"Y Nefedova","year":"2007","unstructured":"Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA, Gabrilovich DI. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 2007;67(22):11021\u201328. https:\/\/doi.org\/10.1158\/0008-5472.Can-07-2593.","journal-title":"Cancer Res"},{"key":"1011_CR254","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3389\/fimmu.2020.01680","volume":"11","author":"PD De Cicco","year":"2020","unstructured":"De Cicco PD, Ercolano G, Ianaro A. The New Era of cancer immunotherapy: targeting myeloid-derived suppressor cells to overcome immune evasion. Front Immunol. 2020;11:1680. https:\/\/doi.org\/10.3389\/fimmu.2020.01680.","journal-title":"Front Immunol"},{"key":"1011_CR255","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.intimp.2018.08.007","volume":"63","author":"RP Tobin","year":"2018","unstructured":"Tobin RP, Jordan KR, Robinson WA, Davis D, Borges VF, Gonzalez R, et al. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. Int Immunopharmacol. 2018;63:282\u201391. https:\/\/doi.org\/10.1016\/j.intimp.2018.08.007.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"1011_CR256","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1158\/0008-5472.Can-17-3415","volume":"78","author":"R Bauer","year":"2018","unstructured":"Bauer R, Udonta F, Wroblewski M, Ben-Batalla I, Santos IM, Taverna F, et al. Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of antiangiogenic therapy. Cancer Res. 2018;78(12):3220\u201332. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-3415.","journal-title":"Cancer Res"},{"issue":"1","key":"1011_CR257","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Sig Transduct Target Ther. 2021;6(1):362. https:\/\/doi.org\/10.1038\/s41392-021-00670-9.","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"1011_CR258","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","volume":"120","author":"C Groth","year":"2019","unstructured":"Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J, et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer. 2019;120(1):16\u201325. https:\/\/doi.org\/10.1038\/s41416-018-0333-1.","journal-title":"Br J Cancer"},{"issue":"3","key":"1011_CR259","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3390\/cells9030561","volume":"9","author":"AMK Law","year":"2020","unstructured":"Law AMK, Valdes-Mora F, Gallego-Ortega D. Myeloid-derived suppressor cells as a therapeutic target for cancer. Cells. 2020;9(3):561. https:\/\/doi.org\/10.3390\/cells9030561.","journal-title":"Cells"},{"issue":"1","key":"1011_CR260","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52(1):17\u201335. https:\/\/doi.org\/10.1016\/j.immuni.2019.12.011.","journal-title":"Immunity"},{"issue":"9","key":"1011_CR261","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","volume":"20","author":"S Jaillon","year":"2020","unstructured":"Jaillon S, Ponzetta A, Di Mitri DD, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20(9):485\u2013503. https:\/\/doi.org\/10.1038\/s41568-020-0281-y.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1011_CR262","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41423-020-00558-8","volume":"18","author":"Y Wen","year":"2021","unstructured":"Wen Y, Lambrecht J, Ju C, Tacke F. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell Mol Immunol. 2021;18(1):45\u201356. https:\/\/doi.org\/10.1038\/s41423-020-00558-8.","journal-title":"Cell Mol Immunol"},{"key":"1011_CR263","doi-asserted-by":"publisher","unstructured":"Burgener SS, Schroder K. Neutrophil extracellular traps in Host defense. Cold Spring Harb Perspect Biol. 2020;12(7):a037028. https:\/\/doi.org\/10.1101\/cshperspect.a037028.","DOI":"10.1101\/cshperspect.a037028"},{"issue":"18","key":"1011_CR264","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1182\/blood-2013-10-463646","volume":"123","author":"K Martinod","year":"2014","unstructured":"Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood. 2014;123(18):2768\u201376. https:\/\/doi.org\/10.1182\/blood-2013-10-463646.","journal-title":"Blood"},{"issue":"6","key":"1011_CR265","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","volume":"184","author":"M Dougan","year":"2021","unstructured":"Dougan M, Luoma AM, Dougan SK, Wucherpfennig KW. Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell. 2021;184(6):1575\u201388. https:\/\/doi.org\/10.1016\/j.cell.2021.02.011.","journal-title":"Cell"},{"key":"1011_CR266","doi-asserted-by":"publisher","unstructured":"Naing A, Papadopoulos KP, Pishvaian MJ, Rahma O, Hanna GJ, Garralda E, et al. First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours. bmjonc. 2024;3(1):e000249. https:\/\/doi.org\/10.1136\/bmjonc-2023-000249.","DOI":"10.1136\/bmjonc-2023-000249"},{"issue":"8","key":"1011_CR267","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","volume":"2","author":"CB Rodell","year":"2018","unstructured":"Rodell CB, Arlauckas SP, Cuccarese MF, Garris CS, Li R, Ahmed MS, et al. TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat Biomed Eng. 2018;2(8):578\u201388. https:\/\/doi.org\/10.1038\/s41551-018-0236-8.","journal-title":"Nat Biomed Eng"},{"issue":"4","key":"1011_CR268","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","volume":"17","author":"JD Martin","year":"2020","unstructured":"Martin JD, Cabral H, Stylianopoulos T, Jain RK. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat Rev Clin Oncol. 2020;17(4):251\u201366. https:\/\/doi.org\/10.1038\/s41571-019-0308-z.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1011_CR269","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1038\/s41467-019-11911-5","volume":"10","author":"F Zhang","year":"2019","unstructured":"Zhang F, Parayath NN, Ene CI, Stephan SB, Koehne AL, Coon ME, et al. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat Commun. 2019;10(1):3974. https:\/\/doi.org\/10.1038\/s41467-019-11911-5.","journal-title":"Nat Commun"},{"issue":"1","key":"1011_CR270","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","volume":"2","author":"SE Ackerman","year":"2020","unstructured":"Ackerman SE, Pearson CI, Gregorio JD, Gonzalez JC, Kenkel JA, Hartmann FJ, et al. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat Cancer. 2020;2(1):18\u201333. https:\/\/doi.org\/10.1038\/s43018-020-00136-x.","journal-title":"Nat Cancer"},{"key":"1011_CR271","doi-asserted-by":"publisher","first-page":"107160","DOI":"10.1016\/j.phrs.2024.107160","volume":"203","author":"C Fu","year":"2024","unstructured":"Fu C, Tong W, Yu L, Miao Y, Wei Q, Yu Z, et al. When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside? Pharmacological Res. 2024;203:107160. https:\/\/doi.org\/10.1016\/j.phrs.2024.107160.","journal-title":"Pharmacological Res"},{"issue":"2","key":"1011_CR272","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3322\/caac.21705","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Carmagnani Pestana RC, Corti C, Modi S, Bardia A, Tolaney SM, et al. Antibody\u2013drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clinicians. 2022;72(2):165\u201382. https:\/\/doi.org\/10.3322\/caac.21705.","journal-title":"CA Cancer J Clinicians"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-01011-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-01011-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-01011-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:47:35Z","timestamp":1792190855000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-01011-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":272,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1011"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-01011-0","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"10 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"142"}}